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I Introduction 
Modern biotechnology started with the development of recombinant DNA technology (Cohen 
et al. 1973) which allows genes to be isolated from one organism and inserted it into a 
different one. Today the production of monoclonal antibodies (mAbs) (Köhler and Milstein 
1975) and recombinant antibodies (rAbs) in mammalian cells is a standard technique. 
Economic analyses and reviews have shown that there will be a capacity crunch in the 
production of recombinant proteins (Fox 2001; Gura 2002; BioTechConsult et al. 2005), and 
mammalian cell culture will not meet all production demands in the future (Hood et al. 2002). 
Enormous manufacturing capacities are required for therapeutics, such as antibodies, that 
are usually required in high doses (Casadevall 1996). Monoclonal antibodies currently 
represent the fastest growing pharmaceutical market segment, with a potential to reach 
worldwide sales of US$ 20 billion by the year 2010 (Gottschalk 2005). The strong growth of 
the biopharmaceutical industry is driven by monoclonal antibodies, with a 43% compounded 
annual growth rate. In 2010, up to 17 metric tons of monoclonal antibodies will probably be 
produced to assure the demand of new antibody-based therapies (Low et al. 2007). 
At present two expression platforms are used for the production of the majority of 
recombinant proteins: bacteria (mainly Escherichia coli) and mammalian cell culture 
(primarily CHO (Chinese Hamster Ovary) cells, two murine myeloma lines and human retinal 
PER.C6 cells (Chu and Robinson 2001)). Bacteria use inexpensive media and accumulate 
large amounts of target protein in inclusion bodies. Purification strategies for inclusion bodies 
are well established. However, they lack the ability to carry out posttranslational 
modifications such as glycosylation and complex folding. Conveniently, mammalian cells 
often secrete the target protein into the supernatant, which makes cell disruption 
unnecessary and provides a broth with low foreign protein levels for easy downstream 
processing. Cultivation of mammalian cells is a major cost factor due to expensive media and 
facilities. Additionally the risk of contamination with human pathogens intensifies the 
purification efforts. Plants provide an attractive complement to these established expression 
platforms, particularly for the production of antibodies, hormones, human blood products, 
growth regulators and vaccines (Fischer and Emans 2000; Giddings 2001; Fischer et al. 
2004). In 1989 the first antibody was expressed in tobacco (Hiatt et al. 1989). Today different 
kinds of antibodies and their derivatives can be expressed in plants, e.g. full size serum 
antibodies, secretory antibodies, minibodies, diabodies as well as antigen-binding (Fab) 
fragments and mono- and bispecific single chain variable fragments (scFvs) with optional 
fusion proteins (Ma et al. 2003; Ko and Koprowski 2005). 
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Figure I-1: Antibodies and antibody fragments expressed in transgenic plants. 
(From Fischer et al. (2003)) 
Transgenic plants are generated by two standard techniques: Agrobacterium-mediated 
transformation (Schillberg et al. 2002; Wang and Li 2002) and particle bombardment (Iida et 
al. 1991; Nishihara et al. 1993). The absence of human pathogens and the ability to fold and 
assemble complex proteins accurately are advantages for protein production by plants 
(Giddings et al. 2000; Staub et al. 2000; Ma et al. 2003; Zhang et al. 2003). The differences 
in post-translational modification between plants and mammals are still an issue and need to 
be evaluated on a case by case basis. Plant complex glycans contain α(1,3)-fucose and 
core-xylose residues (Cabanes-Macheteau et al. 1999) that are not present in human 
glycoproteins. Only the proteins targeted for retention in the endoplasmatic reticulum have 
identical glycans in mammals and plants (Gomord et al. 2005). Nevertheless, plant-specific 
glycans could influence Fc receptor binding (Nose and Wigzell 1983) or antibody clearance 
(Rademacher et al. 1983) in a positive manner (Miele 1997). A promising development to 
avoid problems caused by plant glycans is the use of transgenic plants that lack the capacity 
to synthesize these residues (von Schaewen et al. 1993; Huether et al. 2005). 
Plant cells can be cultivated in suspension cultures in the same way as mammalian cells 
(Torres et al. 1999), or as intact plants in the greenhouse, comparable with transgenic 
animals. Plant cell culture offers the advantage of inexpensive media compared to 
mammalian cells (Hellwig et al. 2004). Transgenic plants cultivated in the greenhouse or in 
the field offer the advantage of simple and inexpensive scale up (Hiatt et al. 1989; Ma and 
Hein 1995; Schillberg et al. 1999), which is achieved simply by cultivating larger areas of 
land, as opposed to building new fermentation facilities. For cultivation, well known traditional 
techniques from food and feed crops can be employed (Fischer et al. 2003). Targeting the 
protein of interest to specific plant storage organs such as seeds or tubers enables 
unprocessed plant material to be stored for an prolonged period, so that upstream production 
can be uncoupled from downstream processing with no deleterious effects on the product 
(Kusnadi et al. 1998). 
Tobacco is advantageous as a production platform because certain well-characterized 
cultivars have been cultivated for several hundred years and the procedures are well 
established. It is a non-feed/non-food plant, and therefore does not interfere with human or 
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animal nutrition (Sparrow et al. 2007). Furthermore, tobacco produces a large amount of 
biomass and the transformation technology is well established and robust (Schillberg et al. 
2005). The short generation time is advantageous for breeding, making tobacco an ideal 
platform for protein production. 
I.1 Downstream processing of recombinant proteins 
The peculiar nature of biopharmaceuticals as products of living organisms requires unique 
and challenging approaches compared to “well defined” chemically synthesized drugs. Even 
at this early phase of process development, long before clinical evaluation or market 
authorisation of product, it is essential to generate robust, reliable forecast data to allow 
smooth technology transfer from the laboratory to the future Good Manufacturing Practice 
(GMP) process, and to assist in taking strategic economic decisions. Defining, implementing, 
documenting and evaluating the individual unit operations which, taken together, form a 
production process, is a critical task and requires considerable expertise. In the “plant-
upstream” section, cultivations are performed on a benchtop scale and up-scaled to the pilot 
scale to assess the reproducibility of the process as well as the influence of cultivation 
conditions, fertilizer additives etc. on the quality and consistency of the product. In the 
“downstream” section, the sequence of operations to isolate the product is defined and 
tested for its ability to remove contaminants such as host cell proteins, DNA, endotoxins and 
viruses to predefined levels without compromising product quality. This is a complex task 
although the arsenal of methods for antibody purification is relatively small, with Protein A as 
the essential step and (membrane) filtration, possibly with additional virus inactivation steps. 
Definition and evaluation of analytical methods for quality control purposes also starts in this 
phase. So, while there is still room for modification and optimization, failure to keep future 
GMP processes in mind can have disastrous consequences. 
Current yields of plant made pharmaceuticals (PMPs) are still too low for economic 
competition with mammalian cell cultures. They are comparable with the situation 20 years 
ago, when expression levels were far below the 15–27 g of antibody per liter cell culture fluid 
(CCF) that can be achieved in some of today’s best performing cell lines, such as PER.C6 
(Macdonald 2008; Mansell 2008). Furthermore, there is regulatory uncertainty regarding the 
purification of pharmaceuticals from plant material, and downstream processing (DSP) is still 
the bottleneck in PMP production. Although the upstream production of plant biomass can be 
achieved at a large scale, the processing of this material is problematic. The greatest 
differences compared to CCF are found in the early recovery and DSP steps. The plant host 
and final destination of the recombinant protein influences the selection of unit operations 
before purification. The handling of transgenic plant raw material from post-harvest to final 
formulation can be divided into three general stages: material pre-processing; protein 
extraction and solid/liquid clarification; and protein purification (Nikolov and Woodard 2004). 
INTRODUCTION 
  4 
Plant material usually needs grinding for the extraction of the target molecule. Filtration of a 
viscous extract with very high particle load is different to CCF filtration, thus requiring the 
most process development. To remove the target from this complex extract selective capture 
and polishing steps need to be invented. For industrial processes, the purification of 
antibodies from the supernatant of mammalian cells is well established, using either Protein 
A (Kelley 2007) or (non)-peptide ligands as an alternative (Kihira and Aiba 1992; Li et al. 
1998; Teng et al. 2000; Roque et al. 2007). Although the final steps usually consist of 
standard chromatography procedures, and may be applied to clarified plant extracts, the 
preceding clarification steps (centrifugation or microfiltration) still need to be optimized. Once 
captured the following steps in DSP are similar to CCF processing. To be competitive with 
animal cell culture in the future, cost-efficient DSP is required with costs at least comparable 
to mammalian CCF processing but preferably lower. The simplicity of purification is therefore 
a major cost factor directly affecting the choice of the expression platform (Menkhaus et al. 
2004). 
I.2 Regulatory considerations for production of PMPs 
The initial process steps upstream of 0.2 µm filtration including growth, harvest, extraction 
and clarification are most problematic DSP stages. Once clarified, the extract can be 
transferred into the clean room and processed further according to GMP. Fermentation can 
be carried out in closed systems without contact between product and environment. 
Cultivation of whole plants under sterile conditions would be too expensive, thus overcoming 
the advantage of inexpensive scale-up (Ma et al. 2005) and natural absence of human 
pathogens. However, it is not possible to transfer whole plants into the clean-room 
environment. At present the authorities in Europe and America cannot provide guidelines for 
the production of active pharmaceutical ingredients (API) from higher plant material. Thus, 
companies and research institutes have to face this regulatory uncertainty by working 
together with the authorities, especially with the European Medicines Agency (EMEA) for 
Europe. In 2002, EMEA released draft legislation regarding PMPs with points to consider 
(EMEA 2002). Consultations between the authority and industrial and scientific researchers 
followed, to discuss points of interest. In this draft, for example, “the absence of viral […] 
contamination” was postulated, including non-human pathogens (i.e. plant viruses). In 2006 
EMEA released a second draft, which switched from “points to consider...” to “Guideline on 
the quality of biological active substances produced by stable transgene expression in higher 
plants” (EMEA 2006). In this draft, plant viruses were excluded from the purification 
requirements. This development reflects the cooperation needed between authorities and 
manufactures to establish a new regulatory framework for PMPs produced under cGMP 
conditions (Emlay 2002). Only then can plants be considered as an alternative to established 
pharmaceutical production systems (Drossard 2004). 
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I.3 The Pharma-Planta project 
In 2007, 33.2 million people worldwide were known to be infected with HIV, including 2.5 
million new infections; 2.1 million also died of AIDS (WHO 2007). The human 
immunodeficiency virus (HIV) is an enveloped retrovirus that causes acquired 
immunodeficiency syndrome (AIDS). During the progression of this disease, the immune 
system of the patient is destroyed and AIDS results from opportunistic infections, which 
ultimately prove fatal. Given the immense number of victims of this disease, there are 
demands for effective prevention, treatment, and education. Antibodies, in combination with 
a cellular response to the virus, potentially offer the most effective HIV treatment (Zolla-
Pazner 2004) because they can bind several different proteins in HIV. By binding to these 
proteins, the infection cycle or virus proliferation can be interrupted, thus repressing the 
infection. If rolled out as a standard therapeutic approach, very large amount of antibody 
would be required, and PMPs may provide an answer to the current economic challenges in 
very large-scale biomanufacturing. 
The Pharma-Planta program unites 39 academic research laboratories and companies 
representing 11 countries within the EU as well as South Africa. These participants work 
together within the context of an EU Sixth Framework Integrated Project to develop 
technologies for the production of plant-made pharmaceuticals. Because proof of the PMP 
concept was achieved in previous research (Ma and Hein 1995; Fischer and Emans 2000; 
Stoger et al. 2002; Schillberg et al. 2003; Fischer et al. 2004), the aim of the Pharma-Planta 
program is to develop an entire production chain by taking candidate pharmaceutical 
molecules from the expression platform through all stages of the production chain ultimately 
to initiate phase I human trials in Europe, which have not been formally addressed within the 
EU. Furthermore the aim is to help define the regulatory framework for PMP production, and 
thus to gain permission for clinical phase I studies. The final candidate for this purpose is the 
monoclonal antibody 2G12, which will be produced in transgenic tobacco. The antibody will 
be administered in gel form onto the mucosal surface of the vagina. Preclinical trials will be 
carried out using rabbits. 
I.4 The recombinant antibody 2G12 
Antibodies are complex glycoproteins produced by the vertebrate immune system and are 
part of the immunoglobulin (Ig) family. They are produced in the B-lymphocytes to intercept 
and neutralize pathogens. The Y-shape structure consists of two identical heavy chains 
(HCs), connected by disulfide bonds in the hinge region. The HCs (~50 kDa) mostly consist 
of three constant regions (CH) and one variable region (VH). Each HC is linked to a light chain 
(LC) (~25 kDa), consisting of one constant (CL) and one variable region (VL). In the variable 
regions of both VH and VL, three hypervariable domains represent the “complementary 
determining regions” (CDRs), which are stabilized by four framework regions (Kabat et al. 
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1992). The variable regions of both the light and HCs build up the antigen-binding site. These 
binding sites bind specifically to their antigen. 
The antibody 2G12 was chosen within the scope of the Pharma-Planta project as a 
promising anti-HIV candidate (Armbruster et al. 2002; Stiegler et al. 2002) for preventing viral 
infections. This antibody targets neutralizing epitopes on the envelope of HIV-1, but can only 
counter cell-free viruses (Trkola et al. 1996). The epitopes consist of high-mannose 
structures located on the silent face of the surface protein gp120 (Calarese et al. 2003; Roux 
et al. 2004), although without a highly restrictive carbohydrate specificity (Calarese et al. 
2005). Amino acid side chains do not participate in antibody binding (Scanlan et al. 2002). 
The antibody 2G12 features an unusual VH domain swap, so that the molecule is neither Y- 
nor T-shaped but linear, due to the parallel orientation of the antibody arms. This facilitates 
the bivalent binding of epitopes that are only 35 Å apart (Calarese et al. 2003). Two 
additional glucan-binding sites are found at the VH/VH-interface, “providing a virtually 
continuous surface for multivalent recognition with interaction sites that match the 
geometrical spacing of the carbohydrate cluster on gp120” (Calarese et al. 2003). 
 
Figure I-2: The antibody 2G12 and its target gp120. 
(Figure from Calarese et al. (2003)) The VH, VL, CH1 and CL regions are shown. N-glycans at positions 332 and 
392 are thought to be critical for binding, whereas N-glycans at position 339 are not critical, but are supposed to 
interact with the VH/VH interface (Calarese et al. 2003). 
I.5 Objectives 
The aim of this work was to develop and optimize downstream processing strategies to purify 
the recombinant antibody 2G12 from transgenic tobacco leaves. The downstream processing 
steps investigated in the project included dispersion and extraction, filtration and clarification 
as well as capture, intermediate purification and polishing chromatography. Through the use 
of new methods and techniques such as membrane chromatography, a robust, scalable and 
efficient process was established as a basis for later production under GMP. Depth filtration 
as well as membrane-based technologies such as cross-flow filtration, membrane 
chromatography and other new devices was evaluated. The aim was to scale up processing 
from laboratory to pilot scale (up to 10 kg fresh weight plant material per batch). The 
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processes were monitored with techniques such as electrophoreses, immunoblotting, surface 
plasmon resonance spectroscopy, mass spectrometry, protein and DNA analytics and 
glycoanalytics as well as neutralizing assays. 
Figure I-3 compares possible purification strategies proposed in the project’s initial stages. 
The first task was to test the dispersion of tobacco leaf material at small and large scales, 
then filtration techniques for the elimination of large particles and fibers were evaluated. 
Further clarification was tested by depth filtration and hollow fiber cross-flow filtration, in 
combination with ultrafiltration. Direct capture of the antibody from unclarified extract was 
examined with Sartobind Direct. Antibody capture from clarified extract was investigated by 
affinity and non-affinity column chromatography as well as affinity membrane techniques. 
The eluate from the affinity chromatography step was polished by downstream 
chromatographic steps. 
 
Figure I-3: Progress diagram of possible ways to achieve the objectives. 
Process development looks at the whole purification series. Part I covers the disintegration and extraction of the 
plant material. Part II concerns the depletion of fibers from the crude extract. Further clarification and final 0.2 µm 
filtration are addressed in part III. Antibody capture is covered in part IV by affinity or non-affinity chromatography. 
Part V affects the intermediate purification and final polishing of the antibody. 
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II Materials and Methods 
II.1 Materials and Equipment 
II.1.1 Chemicals and Consumables 
Chemicals and consumables were purchased from Bio-Rad (Munich, Germany), Fermentas 
(St. Leon-Rot, Germany), GE Healthcare (Munich, Germany), Greiner Bio-One 
(Frickenhausen, Germany), Invitrogen (Eggenstein, Germany), KMF Laborchemie (St. 
Augustin, Germany), Millipore (Eschborn, Germany), MWG-Biotech (Ebersberg, Germany), 
NALGENE® (Neerijse, Belgium), NCSRT (Apex, NC, USA), Nunc (Biebrich, Germany), 
Pierce (Rockford, IL, USA), Qiagen (Hilden, Germany), Roth (Karlsruhe, Germany), Sarstedt 
(Nuembrecht, Germany), Sartorius Stedim Biotech (Göttingen, Germany), Schott-Glaswerke 
GmbH (Neufahrn/San Diego), Sigma (Deisenhofen, Germany), Whatman (Maidstone, 
England), VWR (Darmstadt, Germany). P. A. grade or the highest grade available was 
ordered. 
II.1.2 Buffers and solutions 
The following buffers and solutions were used. For abbreviations see VII.1. 
Table II-1: Buffers for analytics 
10x PBS (pH 7.4)  PBS-T (pH 7.4) 
1370 mM NaCl 
27 mM KCl 
81 mM Na2HPO4 
15 mM KH2PO4 
 1x PBS 
0.05 % (w/v) Tween-20 
   
   
AP-buffer (pH 9.6)  Blotting buffer 
100 mM Tris-HCl 
100 mM NaCl 
5 mM KCl 
25 mM Tris-HCl 
192 mM glycine 
20 % (v/v) methanol 
 
 
 
 
HBS-EP-buffer (pH 7.4)   
10 mM HEPES 
150 mM NaCl 
3.4 mM KCl 
  
 
Table II-2: Buffers and solutions for plant processing 
Extraction buffer (pH 7.5) (BA)  Extract pH-adjustment solution (BH) 
400 mM Na3PO4 500 mM NaCl 
40 mM Na2HPO4 
10 mM NaH2PO4 
10 mM Na2S2O5 
adjust pH with 10 M NaOH 
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Table II-3: Buffers and solutions for Protein A membrane chromatography 
Protein A equilibration buffer pH 7.5 (BA)  Protein A washing buffer pH 7.5 (BB) 
500 mM NaCl  10 mM NaH2PO4 
40 mM Na2HPO4  adjust pH with 1 M NaOH 
10 mM NaH2PO4   
10 mM Na2S2O5   
adjust pH with 10 M NaOH   
   
   
Protein A elution buffer pH 3.2 (BC)  Protein A CIP solution (BD) 
100 mM glycine  50 mM NaOH 
100 mM fructose  2 M NaCl 
adjust pH with 37% (w/v) HCl   
   
   
Protein A storage buffer pH 7.5 (BE)  BioProcess CIP solution (BF) 
20 mM NaH2PO4  1 M NaOH 
25% (v/v) ethanol   
adjust pH with 1 M NaOH   
   
   
BioProcess storage solution (BG)   
25% (v/v) ethanol   
 
Table II-4: Buffers and solutions for ceramic hydroxyapatite chromatography 
Low salt buffer pH 6.5 (BJ)  High salt buffer pH 6.5 (BK) 
5 mM NaH2PO4  5 mM NaH2PO4 
adjust pH with 1 M NaOH  860 mM NaCl 
  adjust pH with 1 M NaOH 
   
   
CIP buffer pH 6.5  CIP buffer (BH) 
500 mM NaH2PO4  400 mM Na3PO4 
adjust pH with 10 M NaOH   
   
   
Storage solution (BF)   
1 M NaOH   
 
Table II-5: Buffers and solutions for concentration and diafiltration of 2G12 
CFF skid equilibration buffer pH 6.5  Dialysis solution pH 5-7 
5 mM NaH2PO4  0.9% (w/v) NaCl 
860 mM NaCl   
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Table II-6: Buffers and solutions for Cu-chelating Sepharose chromatography, concentration and 
diafiltration 
Immobilizing solution (BL)  Equilibration buffer (pH 7.5) (BM) 
100 mM CuSO4  25 mM NaH2PO4 
  600 mM NaCl 
  adjust pH with 1 M NaOH 
   
   
Elution buffer (pH 7.5) (BN)  Strip solution (BO) 
25 mM NaH2PO4  50 mM EDTA 
600 mM NaCl  500 mM NaCl 
100 mM imidazole   
adjust pH with 1 M NaOH   
   
   
CIP solution (BF)  Storage solution (BG) 
1 M NaOH  25% (v/v) ethanol 
   
   
Dialysis buffer pH 7.5 (BP)   
25 mM NaH2PO4   
 
II.1.3 Plant material dispersion units 
The laboratory-scale unit Reactron2 (RT2) (Kinematica, Switzerland) is a laboratory scale 
device to process up to 500 g leaf material. It comprises two independent rotor/stator 
components for dispersion. 
 
Figure II-1: Laboratory scale dispersion unit RT2. 
The skid comprises two separate rotor/stator units, connected to a coolable vessel. Up to 500 g of plant biomass 
can be processed. 
The pilot-scale unit Reactron50 (RT50) (Kinematica, Switzerland) was assembled according 
to former laboratory-scale experience. The RT50 consists of a coolable 70 l tank (~50 l 
working volume), which contains an anchor stirrer, temperature probe and the pre-dispersion 
unit Polytron as well as piping and electronic control cabinet. Piping enables recirculation 
through the fine dispersion unit Megatron. The stirrer, Polytron and Megatron are driven by 
separate engines. The Polytron and Megatron are adjustable from 0-3000 rpm and 
MATERIALS AND METHODS 
 11 
0-12,000 rpm, respectively, resulting in peripheral speeds of 11 m/s and 40 m/s, respectively. 
Both dispersion units function according to the rotor/stator principle. 
(a)      (b) 
Figure II-2: Pilot scale dispersion unit RT50 (a) and inside view of the pre-dispersion unit (b). 
The device comprises a cooled vessel, connected to two chopping generators working according to the 
rotor/stator principle. The Polytron generator for the initial dispersion and the anchor stirrer are shown in (b). 
The Polytron features a one-rim generator with larger teeth gaps for processing whole 
leaves; the Megatron holds a three-row generator with small gaps for processing pre-
disrupted particles in the extract. Modifications installed in the Polytron and Megatron were 
carried out by the RWTH workshop and Kinematica AG, respectively. 
II.1.4 Further equipment 
• Bags: Flexboy 50 l (Sartorius Stedim Biotech GmbH, Göttingen, Germany), Flexel 3D 
bag (Applied Critical Fluids GmbH, Mannheim, Germany) 
• Balances: BP121S, BP6100, BP610, IF Flat-bed Scale 150 kg, TE6101 (Sartorius 
Mechatronics, Göttingen, Germany) 
• Bioreactor: Applicon 30 l working volume (Applicon, Netherlands) 
• Camera: Canon EOS 350D (Krefeld, Germany) 
• Centrifuges: Eppendorf MiniSpin (Eppendorf, Wesseling-Berzdorf); Avanti J-20 
(Beckman Coulter GmbH, Krefeld, Germany) 
• Cooling coil: beer cooling coil (Schankanlagen Koch & Ambient-Gastro-online GmbH, 
Wadern, Germany)  
• Cooling unit: RTE-200D (NESLAB,  Newington, NH, USA) 
• Cooling vessel: LevTech LT-JTBB051 (LevTech, Bradford, PA, USA) 
• Conductivity meter: Cond 315i (WTW GmbH, Weilheim, Germany) 
• Chromatography columns: XK16/20, BPG 100, Index 140, Superdex 200 10/30 (GE 
Healthcare, Uppsala, Sweden); BioCart (YMC, Dinslaken, Germany); Sartobind 
System holder (Sartorius Stedim Biotech GmbH, Göttingen)  
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• Chromatography controller: BioProcess skid, ÄKTA Pilot skid, ÄKTA Purifier100, 
ÄKTA Purifier10, ÄKTA Explorer10 (GE Healthcare, Uppsala, Sweden) 
• Chromatography media: affinity chromatography membranes (Sartorius Stedim 
Biotech GmbH, Göttingen, Germany); Mab Select, Capto MMC, Capto Adhere (GE 
Healthcare, Uppsala, Sweden); Hydroxyapatite (Bio-Rad, Hercules, CA, USA) 
• Cross flow skid: Purosep LT-2 (NCSRT, Apex, NC, USA); Sartoflow Alpha, Vivaflow 
200 (Sartorius Stedim Biotech AG, Göttingen, Germany) 
• Dispersion: Waring Blender (VWR, Darmstadt, Germany); Reactron50, Reactron2 
(Kinematica, Luzern, Switzerland) 
• Electrophoresis equipment: gel running chamber, blotting chamber (Invitrogen, 
Karlsruhe, Germany) 
• Filter: Sartopure PP2, Sartoclear, Sartopore2 (Sartorius Stedim Biotech GmbH, 
Göttingen, Germany); bag filter (3M, Neuss, Germany) 
• Filter housing: Sartocell 12” (Sartorius Stedim Biotech GmbH, Göttingen, Germany); 
TL-1 (3M, Neuss, Germany) 
• Flow meter: Promag 50 (Endress+Hauser, Weil am Rhein, Germany) 
• Magnetic stirrer: RCT basic (IKA Werke GmbH & Co. KG, Staufen, Germany); 
Variomag mobil (Daytona Beach, FL, USA) 
• pH meter: BP-11 (Sartorius Stedim Biotech GmbH, Göttingen, Germany); WTW 
Inolab (WTW GmbH, Weilheim, Germany) 
• Pipettes: Pipetman P1000, P200, P20 (Gilson, Villiers le Bel, France) 
• Pressure gauges: Ceraphant (Endress+Hauser, Weil am Rhein, Germany); Anderson 
pressure gauge (ITE, Elze, Germany) 
• Pumps: Masterflex L/S Digital Dispenser, Masterflex I/P Digital (Masterflex AG, 
Gelsenkirchen, Germany); Quattroflow 150S (Quattroflow, Hardegsen-Hevensen, 
Germany) 
• Sanitary fittings: T-pieces, TC-clamps, seals (ITE, Elze, Germany; Linnemann, 
Tubingen, Germany) 
• Scanner: Arcus II Scanner with AGFA FotoLook 3.5 (AGFA, Cologne, Germany) 
• SPR measurement unit: BiaCore 2000 (GE Healthcare, Uppsala, Sweden) 
• Stirrer engine: R42W3-75/2 (Heytec, Munich, Germany) 
• Turbidity meter: 2100P ISO (Hach Lange, Düsseldorf, Germany) 
• Vacuum evaporator: Rotavapor RII in combination with vacuum pump V-710 (Büchi 
Labortechnik, Essen, Germany) 
• Vessels: 5 l, 10 l and 20 l Nalgene-bottle (Novodirect, Kehl/Rhein, Germany); 30 l and 
60 l Rotilabo-UN-Weithalsfass (Roth, Karlsruhe, Germany); 100 l and 200 l drums 
(Applied Critical Fluids GmbH, Mannheim, Germany) 
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II.2 Protein production methods 
II.2.1 Production host Nicotiana tabacum cv. SR-1 
II.2.1.1 Transformation and expression of 2G12 
Transformation of tobacco was carried out by Dr. T. Rademacher, Dr. E. Stoger and M. Sack 
(all RWTH Aachen, Institute for biology VII). Transgenic tobacco lines were regenerated from 
leaves transformed using Agrobacterium tumefaciens. The transformation vector contained 
the genetic elements for expression of the 2G12 full-size antibody (HC and LC coding 
regions), a herbicide resistance gene (encoding phosphinothricin acetyltransferase) as a 
selectable marker and a gene encoding red fluorescent protein (DsRed) as a visual marker. 
The vector was based on the binary plasmid pPAM (GenBank: AY027531). The full-size 
2G12 antibody is encoded by the genes for the 2G12 HC and the 2G12 LC, each fused in-
frame to a signal peptide. The heavy and LC sequences (including their accompanying signal 
peptide sequences) encode proteins identical to the 2G12 antibody chains produced in CHO 
cells (Armbruster et al. 2002). The signal peptides ensure that translation of the fusion 
proteins takes place in the endoplasmic reticulum (ER). After cleaving off the peptide 
sequences in the ER, two heavy and two LCs assemble into a full-size IgG1(κ) antibody. The 
assembled antibodies leave the ER via the secretory pathway and accumulate in the 
apoplasmic space. 
II.2.1.2 Cultivation and harvest of Nicotiana tabacum cv. SR-1 
Cultivation of transgenic Nicotiana tabacum cv. SR-1 was carried out in the greenhouse, and 
took 6–11 weeks from sowing to harvest, depending on temperature, length of daylight, pot 
size and fertilizer. 
Two thousand plants were cultivated for large-scale production under the following 
conditions: 1 ‰ (w/v) fertilizer (Ferty® 2 Mega for irrigation), 16 h photoperiod at 25°C/22°C 
and 70% humidity. Plants were potted 4 weeks after seeding. During cultivation, pests were 
controlled using yellow sticky plates. When the plants started to flower, they were harvested 
manually by removing all leaves except the lowest three from the stem. Yellowish or 
unhealthy looking leaves were excluded from the harvest. Separated leaf material was 
collected in a tray until the next process step. The maximum hold time did not exceed 1 h. 
Plant cultivation was supervised by Dr. T. Rademacher (RWTH Aachen, Institute for biology 
VII). 
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II.2.2 Small and medium scale protein extraction techniques 
Liquid N2 was used for small scale extraction. Up to 1 g of leaf material was frozen in liquid 
nitrogen and ground using a mortar and pestle to a homogenous powder, before extraction 
buffer was added. 
A Waring blender was used for laboratory-scale extraction, when larger amounts of leaf 
material had to be processed. Up to 500 g leaf material was combined with three volumes of 
extraction buffer and disintegrated for 3x 30 s. Because of the enormous turbulent flow, this 
dispersion process also facilitated extraction of the antibody. 
A plate press was used for laboratory-scale extraction to obtain fiber-free plant extract 
without using extraction buffer. Two custom-made aluminium plates (25 x 15 x 2 cm) were 
held together by 12 screws. Up to 20 g of leaves were placed in the middle of the lower plate. 
The upper plate was mounted and the screws tightened by until the pressure between the 
plates was enough to force liquid from the leaves. The lower plate had drains direct the flow 
of plant sap. By separating the plates, leaf material could be rearranged for second and third 
pressing steps. The resulting extract contained almost no plant fibers. 
 
Figure II-3: Custom-made plate press, used for dispersion-free extraction of tobacco leaves. 
The plates were held together with 12 screws. Furrows directed the press juice to the right end to control liquid 
collection. 
RT2 was used for medium-scale processing, and could handle up to 500 g leaf material. To 
facilitate disruption, the leaf size had to be reduced to less than 3 cm by hand, before adding 
extraction buffer and pre-disintegration in the Polytron (4000 rpm, 1 min), followed by fine 
dispersion using the Megatron (11,000 rpm, 6 min). Because of the enormous turbulent flow, 
this dispersion process also facilitated extraction of the antibody. 
II.2.3 Pilot scale dispersion and extraction 
The primary operating mode of the Reactron50 (RT50) consisted of the pre-size reduction of 
the leaf material by Polytron, followed by fine dispersion by Megatron. Therefore three 
volumes of extraction buffer were added to 12 kg fresh weight leaf material. Due to clogging 
of the anchor stirrer and Polytron generator, aggregations had to be removed manually 
several times. A compatible particle size for Megatron was reached after 10-15 min Polytron 
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grinding. The valve at the vessel bottom was opened to enable recirculation through the 
Megatron (12,000 rpm, 15 min) for fine dispersion. 
Leaf material
and buffer
Megatron
Polytron
Outlet
 
Figure II-4: Flow scheme of Reacton50 for dispersion of fresh leaf material. 
After insertion of plant material and buffer, pre-size reduction by Polytron was initiated. Fine dispersion followed in 
a recirculation mode using the Megatron. 
The secondary dispersion mode omitted the second dispersion unit Megatron. The Polytron 
generator tool was replaced with free-rotating blades, and the rotation speed was increased 
to 3600 rpm for 8 min. The temperature was kept below 15°C by cooling. After dispersion, 
the pH of the extract was adjusted to 7.5 by adding 400 mM Na3PO4. When the pH was 
constant ±0.05 pH units for 2 min, the extract was transferred to a filtration unit. 
II.2.4 Clarification strategies 
II.2.4.1 Dead end filtration 
Dead end filtration was achieved using peristaltic pumps (Masterflex) connected to T-fittings 
(Linnemann) and pressure gauges (digital: Endress+Hauser; analog: Anderson) by pressure 
tubing (Masterflex). For filtration, either capsules (Sartorius Stedim Biotech) or bag filters 
(3M) were used. The filter capsules were based on either polypropylene cloth or 
diatomaceous earth. The pre-filtration flow rate was 100 ml/min, 250 ml/min and 1000 ml/min 
for small pre-filter capsules, up-scaled pre-filter capsules and bag pre-filter, respectively. For 
clarification, flow rates of 5 ml/min, 180 ml/min and 500 ml/min were used for the small, pilot 
and large scale processes, respectively. 
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Figure II-5: Generic filtration setup for dead-end filtration. 
Filters were fed by a peristaltic pump with a constant flow rate. Pressure and filtrate turbidity were monitored. 
Depth filters, membrane filters and bag filters were tested. 
Filters were pressure controlled up to 1.5 bars or controlled by turbidity depending on the 
type of filter. Intermediate tanks compensated slightly for different pump rates and facilitated 
cooling below 10°C. 
II.2.4.2  Hollow-fiber cross-flow filtration 
Cross-flow filtration (CFF), also called tangential flow filtration (TFF), is a mode of filtration for 
solid/liquid separation or for diafiltration (van Reis et al. 1991; Berthold and Kempken 1994; 
Kurnik et al. 1995). In contrast to dead-end filtration, the main flow direction is tangential to 
the membrane. Thus, layer-forming particles are removed and inhibition of filter cake 
agglomeration results in an optimal filtrate flow. CFF can be carried out with flat cassettes or 
tubular hollow fibers. Cassettes offer a higher filtration area than hollow fibers in ratio to 
module size and are preferred for processing particle-free solutions. Hollow fibers are 
advantageous for treating particle-containing solutions, like fermenter broth or unclarified 
wine. Different parameters like shear rate or transmembrane pressure can be controlled for 
best operation. Controlling the filtrate flow, also called permeate, using a peristaltic pump 
enables the adjustment of certain transmembrane pressures (TMP), the most important 
process parameter. 
perm
retin pppTMP −+=
2
 Equation II-1 
Hollow-fiber filtration was performed with a Purosep™ LT-2 (NCSRT, Apex, NC, USA) 
filtration skid. 
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Figure II-6: Hollow fiber filtration setup. 
The rotary lobe pump feeds the hollow-fiber module with the unfiltrate at 1.5 bars. The retentate pressure can be 
adjusted using a membrane valve. The permeate pump sets the permeate flow, thus controlling the TMP. 
Sensors measured inlet flow, temperature and pressure. The skid consisted of a rotary lobe 
pump connected to a coolable recirculation vessel and a hollow-fiber filtration (HFF) module 
(GE Healthcare, Germany). The hollow-fiber module had a membrane area of 0.28 m² and a 
length of 60 cm. The lumen diameter was 1.0 mm and the pore size was 0.45 µm. An inline 
flow meter (Endress+Hauser, Germany) was installed between pump and HFF module, as 
well as digital pressure gauges (Endress+Hauser, Germany) at the retentate and permeate 
outlets of the HFF module. The temperature of the recirculation vessel was kept below 15°C. 
Filtration was driven by an inlet pressure of 1.5 bars, resulting in a flow of 15 l/min and a 
shear rate of 15,000 per second. The flow of the permeate pump was set to 60 ml/min to 
gain a TMP of 0.3 bar to 0.5 bar (Equation II-1). 
II.2.5 Chromatographic processing 
Chromatography is a collective name for separation methods basing on physical-chemical 
principles and can be used for analytical or preparative purposes. The mixed substances are 
separated due to their different distribution and/or interactions with the mobile and stationary 
phases. Where the target molecule binds to the stationary phase, elution is facilitated by 
buffers of a certain pH and/or ionic strength. This bind-elute principle is used with 
hydrophobic interaction chromatography (HIC), anion and cation exchange chromatography 
(AEX and CEX), and affinity chromatography (e.g. Protein A chromatography or immobilized 
metal affinity chromatography (IMAC)). The principle of the size exclusion chromatography 
(SEC), also called gel filtration, is not differential binding but separation by molecular size 
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due to the pore structure of the resin. The proteins are eluted after a certain delay, which 
increases as the molecular size decreases due to the time taken to percolate through the 
resin. 
An alternative to packed-bed chromatography is membrane chromatography (MC) (Phillips et 
al. 2005; Zhou and Tressel 2006; Boi 2007; Gottschalk 2008) which offers a high flow rate 
without mass transfer limitation due to its open pore structure. The first applications of MC 
were the removal of impurities (Charlton et al. 1999; Knudsen et al. 2001; Brough et al. 
2002). Nevertheless affinity MC might be suitable for target binding at low initial 
concentration in the feed. In such an application, higher volume flow would be more 
important than high binding capacities. 
Chromatographic columns can be characterized by several parameters. The height of the 
theoretical plate (HETP) indicates the distance to reach a new equilibrium between the 
mobile and stationary phases. It is computed as follows where L is column length: 
N
LHETP =  Equation II-2 
The number of theoretical plates N indicates how often the equilibrium is reached through the 
column (EDQM 2005): 
2
2/1
)(54.5
W
VN e=  Equation II-3 
At the optimum, the reduced height of a theoretical plate H is 2-5 times the average particle 
diameter dp. 
Pd
HETPH =  Equation II-4 
The asymmetry reflects the packing quality and is ideally equal to 1. As a rule of thumb, 
asymmetry factors from 0.7 to 1.4 fall within the optimal range. 
a
bAS =  Equation II-5 
For asymmetry determination a tracer is injected onto the column. At the peak, maximum 
height h and elution volume Ve are determined for the calculation of characteristic 
parameters as shown in Figure II-7. 
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(a)   (b) 
Figure II-7: Parameter identification for asymmetry (a) and HETP (b) determination. 
(Ve – elution volume, h – peak height, a – left peak width at 10% h, b - right peak width at 10% h, W1/2 – total peak 
width at 50% h) 
The capacity of a column is the ability to bind a certain substance. The dynamic capacity is 
determined under flow conditions in a break through curve (Dancette et al. 1999). A 
characteristic value is the capacity at the point when the outlet concentration reaches 10% of 
the feed concentration: 
0
%10, 0*
V
cV
Cap feedfeeddyn =  Equation II-6 
Important for the capacity is the contact time tc between target substance and resin. It is the 
quotient from column volume to volumetric flow rate (vvol) or column height to linear flow rate 
(vlin), 
linvol
c v
L
v
Vt == 0  Equation II-7 
vvol can be transformed to vlin following: 
2*
4
d
vv vollin π=  Equation II-8 
where d is the column diameter. 
Laboratory-scale chromatographic separation of clarified plant extracts was carried out using 
an ÄKTA Purifier 100, Purifier 10 and Explorer 10 (all GE Healthcare, Munich). Large-scale 
experiments were performed using the BioProcess skid (GE Healthcare, Munich). The 
control software was Unicorn 5.1 (GE Healthcare, Munich). The controller can be used in 
manual mode or with programmable methods to achieve a high degree of automation. 
Automated methods for chromatography are shown in VII.4. 
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II.2.5.1 Multimodal cation exchange chromatography 
Multimodal cation exchange (MMC) chromatography was used as a non-affinity capture step. 
This resin offered a salt-tolerant cation exchanger because of a hydrophobic side group 
close to the ion exchange group. 
 
Figure II-8: Chemical structure of the Capto MMC ligand. 
The ligand offers a combination of hydrophobic and ionic side groups as well as hydrogen bonding capabilities. 
(Figure from GE Healthcare) 
A Biocart column 5/20 (YMC, Dinslaken) was packed with 2 ml of MMC resin. After 
equilibration (50 mM sodium acetate, 50 mM NaCl, pH 5.6) clarified plant extract was loaded 
onto the column at a flow rate of 300 cm/h. Elution was initiated by either salt gradient or pH 
step gradient to remove bound antibody from the column. Cleaning in place (CIP) was 
carried out with 1 M NaOH. 
II.2.5.2 Multimodal anion exchange chromatography 
Capto Adhere is a multimodal anion exchange resin used in the flow-through mode for 
negative chromatography. Equilibration was achieved using 25 mM sodium phosphate (pH 
6.5). CIP and regeneration were achieved using standard procedures such as 1 M NaOH 
and equilibration buffer, respectively. 
 
Figure II-9: Chemical structure of the Capto Adhere ligand. 
The ligand offers a combination of hydrogen bonds, anionic exchange and hydrophobic interaction. (Figure from 
GE Healthcare) 
II.2.5.3 Affinity chromatography 
Protein A resins and membranes were used for affinity chromatography in the capture step. 
First purified in 1972 (Sjoquist et al. 1972) Protein A is the industry standard for large-scale 
purification of monoclonal antibodies (Ghose et al. 2005; Hober et al. 2007). Protein A is a 
43 kDa protein displayed on the external cell wall of Staphylococcus aureus. A single 
molecule of Protein A can bind two antibodies via the Fc region at the interface between CH2 
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and CH3 (Diesenhofer 1981; Torigoe et al. 1990) of all human IgG except IgG3 (Langone 
1982). 
Protein A capture was achieved using MabSelect (GE Healthcare, Munich) in an XK 16/20 
column (GE Healthcare, Munich). The bed height was 12.5 cm, resulting in a contact time of 
2.5 min at a flow rate of 300 cm/h. Membrane adsorbers (MAs), type MA 75 Protein A 
(Sartorius Stedim Biotech, Göttingen), were used at a flow rate of 7.5 ml/min resulting in a 
contact of 0.28 min. At larger scales, a prototype MA was used at a flow rate of 20 l/h 
resulting in a contact time of 0.45 min. Sartobind Direct (Sartorius Stedim Biotech, Göttingen) 
was tested as an alternative type of MA. After equilibration, the loading material was 
circulated through the module, tangential over the membrane. In all applications, elution was 
facilitated using a low-pH buffer (pH 3.2) comprising 100 mM glycine and 100 mM fructose 
(Gagnon 1996). 
II.2.5.4 Ceramic hydroxyapatite 
Hydroxyapatite (HA), as a complex ion exchange resin, was used for the separation of 
aggregates and DNA. HA consists of a calcium phosphate phase, which can bind both 
positively and negatively charged ions. 
 
Figure II-10: Crystal structure of hydroxyapatite. 
Hydroxyapatite is a complex of Ca10(PO4)6(OH)2. Its combination of positively and negatively charged matrix ions 
offers complex interactions to all charged molecules. (Figure from Bio-Rad Inc. (Paul et al. 2006)) 
A Biocart column 5/20 (YMC, Dinslaken) was packed with HA media to a bed height of 
10 cm, providing a column volume of 2 ml. For production-scale processing, a BPG 100 
column (GE Healthcare, Munich) was packed to 14 cm bed height, with asymmetry of 0.8–2 
considered acceptable (Equation II-5). 4 mg of antibody per ml of resin were loaded, followed 
by washing with buffer (5 mM NaH2PO4, 380 mM NaCl, pH 6.5). Elution was achieved by 
increasing the conductivity of the buffer (5 mM NaH2PO4, 860 mM NaCl, pH 6.5). CIP was 
carried out at high salt concentration (5 mM NaH2PO4, 2 M NaCl, pH 6.5) and high phosphate 
buffer (400 mM Na3PO4, pH 12). 
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II.2.6 Virus reduction 
Virus removal and inactivation is an important consideration in the production of APIs. In cell 
culture-based processes, several orthogonal methods of virus removal have to be included, 
e.g. removal by virus filtration, inactivation by acid treatment, inactivation by UV-irradiation 
and removal by chromatography. Each method works according to unique different principle, 
addressing different properties of the virus particles. Although human pathogenic viruses 
cannot replicate in plants, a well-characterized virus reduction step was included to ensure 
that adventitious viruses were not able to enter the production process and make it through 
to formulation. 
We chose filtration as a virus removal step because of its ease of implementation and 
process integration. Virosart filters (Sartorius Stedim Biotech, Göttingen), containing a 20 nm 
cutoff membrane, were used for this task, and were monitored by a BioPilot chromatography 
controller. 
II.2.7 Concentration and diafiltration 
Concentration and diafiltration are the final steps in a purification process. Concentration is 
carried out to achieve the desired protein concentration for formulation, and diafiltration is a 
method for buffer exchange, to ensure the API is dissolved in the correct formulation buffer. 
Both can be achieved by ultrafiltration, a type of cross-flow filtration (see II.2.4.2). 
Concentration was carried out using a Hydrosart membrane with a 30 kDa nominal molecular 
weight cutoff (NMWCO) and an area of 0.1 m², operated in a Sartoflow Alpha cross flow skid. 
The membrane was equilibrated in ceramic HA elution buffer (5 mM NaH2PO4, 860 mM 
NaCl, pH 6.5) before applying the antibody solution. Concentration was performed at a TMP 
of 0.5 bars. 
Diafiltration was carried out using a Vivaflow 200 (30 kDa NMWCO Hydrosart membrane, 
200 cm²) cross flow skid (Sartorius Stedim Biotech, Göttingen), run by peristaltic pump. 
Operating parameters were chosen according to the instruction manual. The system was 
equilibrated in ceramic HA elution buffer (5 mM NaH2PO4, 860 mM NaCl, pH 6.5) before 
applying the antibody solution concentrated by the Sartoflow Alpha system. Buffer exchange 
to saline (0.9% NaCl) was performed against seven volumes of saline, resulting in a >99% 
exchanged buffer. Final concentration was carried out after diafiltration using the Vivaflow 
200 module. 
 
 
 
MATERIALS AND METHODS 
 23 
II.2.8 Methods for DsRed purification 
After recombinant antibody 2G12 was captured (see II.2.1. to II.2.5), the remaining plant 
extract was used to isolate DsRed. The following process steps were executed: 
• Protein precipitation by heating to 65°C using a 30 l Applicon reactor in flow-through 
mode (35 l working volume, flow rate 2.75 l/min, average contact time 12.7 min) 
• Cooling to <10°C and precipitate sedimentation overnight 
• Supernatant filtration by 0.3 µm Sartoclear 
• Increasing the salt concentration in the extract by 0.2 M NaCl (to ~0.6 M) 
• 0.2 µm inline filtration on the BioProcess controller 
• Loading to a Cu-immobilized Chelating Sepharose (Index 140 column, 25 cm bed 
height, CV = 3.85 l, average flow of 12 l/h) 
• Washing with buffer M 
• Elution with 100 mM imidazole (buffer N) 
• Concentration by Sartoflow Alpha using 10 kDa NMWCO Hydrosart cassette 
II.3 Stability studies  
A stability study was carried out to investigate possible hold steps in the purification process. 
Neutralized eluate from the first chromatographic step was stored at 2-8°C for 4 weeks and 
the antibody concentration confirmed, as well as the activity and monomer ratio. 
For virus inactivation, a different hold step at pH <4 was studied. Protein A MA eluate was 
stored for 4 h at room temperature (RT) at pH 3.6 before neutralization. After neutralization to 
pH 6.5, the antibody concentration (II.4.1), activity (II.4.1) and monomer content (II.4.5) were 
determined. 
II.4 Analytical assays 
II.4.1 Surface plasmon resonance measurement 
Surface plasmon resonance (SPR) spectroscopy was used to determine antibody 
concentration and activity after binding to Protein A, Protein L and gp120. The three ligands 
were immobilized in individual flow cells on the sensor chip (CM5-rg). Chips were prepared 
by M. Sack (RWTH Aachen, Institute for biology VII). HBS-EP was used as the running 
buffer at 30 µl/min. The simultaneous measurement of concentration and product activity 
allowed the specific activity to be calculated, an important factor for product characterization 
and process evaluation. SPR was the most important tool for concentration and activity 
determination. Both were exclusively measured by SPR except where otherwise stated. SPR 
was used for in-process control and to characterize the eluates after each process step. 
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Figure II-11: Surface plasmon resonance sensogram. 
(Characters: A – CHO2G12; B to H – various samples containing SR-12G12) Red line represents the Protein A 
binding signal on a CM5-rg chip. One measuring cycle consisted of baseline determination, sample injection, 
washing and cleaning. Sample A showed the binding response of CHO2G12 with a known concentration as 
reference. Samples B to H represented different antibody concentrations, e.g. samples B and F were too highly 
concentrated, thus the binding signal exceeded the linear range, visible at the convoluted curve in front of the 
peak maximum. Sample C was in the correct concentration range, and the binding signal increased linearly with 
time. 
II.4.2 Enzyme linked immunosorbent assay (ELISA) 
ELISA (Engvall and Perlmann 1971) is a sensitive detection method for proteins. An indirect 
sandwich ELISA was used to detect antibody 2G12. The antibody GAHFc was immobilized 
overnight at 4°C in a 96-well plate (high binding, Greiner Bio-One, Frickenhausen). 
Saturation was achieved using 2% (w/v) BSA in PBS for 30 min at RT. Sample binding was 
carried out in serial dilution steps for 2 h at RT, followed by three washes with PBST and 
then incubation with detection antibody GAHAPκ (1 h, RT, dilution 1:5000 in PBS). Alkaline 
phosphatase (AP) activity was detected with p-nitrophenolphosphate in AP buffer, and 
quantified in a multichannel photometer, relative to a standard of known concentration. 
II.4.3 SDS-PAGE and staining 
SDS-PAGE (sodium dodecylsulfate polyacrylamide gel electrophoresis) is an analytical and 
preparative method for protein separation (Laemmli 1970). Protein samples were separated 
on 4-12 % (w/v) Bis-Tris NuPAGE™ gels (Invitrogen) under reducing and non-reducing 
conditions following the manufacturer’s instructions. 
Visualization of proteins was achieved by staining with 0.25 % (w/v) Coomassie brilliant blue 
G-250 or silver staining (Shevchenko et al. 1996). Molecular weights were estimated with 
SeeBlue Plus2 markers (Invitrogen, Eggenstein) or PageRuler (Fermentas, St. Leon-Rot). 
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II.4.4 Western blot 
Proteins separated by SDS-PAGE (II.4.3) were electrophoretically transferred onto a 
nitrocellulose membrane (Towbin et al. 1979) using tank blotting equipment (Invitrogen). 
Transfer was carried out at 250 mA for 45 min. After transfer, the membrane was blocked in 
2% (w/v) BSA in PBS for 1 h, then incubated for 1 h at RT with the detection antibody 
(GAHAP, H+L specific, Dianova). Three washes (5 min each) with PBST at RT were carried 
out to remove unbound detection antibody, and the signal was detected with NBT/BCIP 
diluted 1:100 in AP buffer. The reaction was stopped by rinsing in RO water. 
II.4.5 Analytical size exclusion chromatography 
Analytical SEC was carried out on an ÄKTA Explorer 10 connected to an Autosampler A900. 
Separation of 100 μl samples was carried out on a Superdex 200HR 10/30 column at 
0.3 ml/min in 1x PBS containing 0.05% (w/v) NaN3 (EDQM 2005). The automated method is 
described in VII.4.4. 
II.4.6 Nicotine analytics 
Nicotine content was measured by gas chromatography coupled to mass spectroscopy 
(GC/MS). The measurements were carried out by Dr. S. Jennewein (Fraunhofer IME, 
Aachen). Nicotine was extracted as  described by Ko et al. (2004) after adjusting the NaCl 
concentration to 2 M. After acidification, the sample was centrifuged (15,000 g, 30 min) and 
1000 ml of the sample was extracted twice with 500 ml chloroform. Concentrated HCl was 
added to the organic phase to inhibit the evaporation of nicotine (Nakajima et al. 2000). 
Evaporation of the organic phase was accomplished with a Rotavapor (Büchi, Essen) and 
residues were taken up in 3 ml methanol for separation on a Rxi-5MS (30 m, 0.25 mm ID, 
0.25 µm film depth) column (Restek, Bad Homburg) using a GC-2010 followed by analysis in 
a GCMS-QP2010S mass spectrometer (both Shimadzu, Duisburg). Both systems were 
controlled by GCMS Realtime Analysis (Shimadzu, Duisburg). The injection temperature was 
set to 220°C, and a temperature gradient was established from 190°C to 210°C, each 1 min 
hold time, at 8°C/min. The MS voltage was set to 1 kV. Data evaluation was managed by 
GCMS Postrun Analysis (Shimadzu, Duisburg). 
II.4.7 DNA analytics 
Contaminant DNA was quantified by Quant-iT™ PicoGreen® dsDNA Reagent and Kits 
(Invitrogen, Eggenstein) according to the manufacturer’s instructions. Each sample was 
centrifuged (5 min, 16,000 x g) for particle removal and evaluated using a multichannel 
fluorescence photometer. 
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II.4.8 Protein quantification 
Total soluble protein (TSP) was determined according to Bradford (1976). Each sample was 
first centrifuged (5 min, 16,000 x g) for particle removal. BSA in 1x PBS was used as the 
reference protein. 
II.4.9 Turbidity determination 
Turbidimetry measurements were carried out with a turbidimeter 2100P (Hach Lange, 
Düsseldorf). The basis of measurement was light spreading caused by particles (EDQM 
2007). Light intensity was compared at 0° and 90°. 
II.4.10 Mass spectroscopy 
Samples for mass spectroscopy were prepared by SDS-PAGE (II.4.3). After Coomassie or 
silver staining, bands of interests were excised from the gel. In-gel reduction, alkylation and 
digestion were performed and samples analyzed by liquid chromatography electrospray 
ionization mass spectroscopy (LC/MS). Analysis was carried out by M. Küpper (RWTH 
Aachen, Institute for biology VII). 
II.4.11 N-glycosylation analytics 
N-glycans were analyzed by J. Stadlmann and Prof. F. Altmann of the Chemistry Department 
of the BOKU in Vienna. The proteins were separated by SDS-PAGE and the HC bands were 
excised (LCs were not analyzed due to the absence of glycosylation). Tryptic digestion of the 
HC bands created peptides that were separated by chromatography and injected into the 
mass spectrometer. Positive ions were monitored and the glycans were identified and 
quantified based on the summed and deconvoluted spectrum of each glycopeptide’s elution 
region. Further information about N-glycan analytics can be found in Strasser et al. (2008). 
II.4.12 Syncytium inhibition assay 
The syncytium inhibition assay was performed by H. Quendler and G. Stiegler from Polymun 
Scientific in Vienna. The IC50 values (required drug concentration for 50% inhibition of viral 
replication in vitro (FDA 2008)) of 2G12 from different sources were compared and 
evaluated. This assay is described in more detail by Trkoler et al. (1996) and Strasser et al. 
(2008). 
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III Results and Discussion 
III.1 Screening of extraction buffers 
To screen for optimal extraction buffers, 0.75 g leaf material was ground with liquid N2 (II.2.2) 
and 1.5 ml of different extraction buffers (citrate, Tris, phosphate, PBS, boric acid and 
acetate) were screened at a concentration of 0.2 M to achieve sufficient buffer capacity. TSP 
and antibody concentration were analyzed using the Bradford assay (II.4.8) and ELISA 
(II.4.2), respectively. 
The pH optimum for extraction of antibody (~8 µg/ml) was 5–8 and that for TSP (1.6 mg/ml) 
was 7–8. At pH 4, neither TSP (0.1 mg/ml) nor 2G12 (0.7 µg/ml) was extracted in significant 
amounts. At pH >8, TSP increased slightly (1.75 mg/ml), but antibody extraction decreased 
(6.7 µg/ml). The choice of buffer solution had little influence on 2G12 extraction, as different 
buffers performed similarly. The addition of NaCl resulted in a higher overall extraction of 
TSP as well as 2G12. The highest 2G12 levels were obtained by using 0.2 M Tris, 0.5 M 
NaCl, pH 7-8 and 0.2 M potassium phosphate, 0.5 M NaCl, pH 6-8. No significant change in 
extraction efficiency was obtained when lowering the buffer capacity by using 50 mM of 
buffering substance, but for further up-scaling, the use of 50 mM phosphate buffer pH 7.5 
would be preferred over the much more expensive Tris buffer. 
III.2 Vacuum filtration and plate pressing 
A crude extract was initially generated by using a Waring blender in the laboratory-scale 
process (II.2.2). Vacuum filtration was tested to remove fibers from crude extract, but this 
was not successful because of early clogging of the filter paper and the filter cake itself. Only 
1 ml crude extract could be filtrated per square centimeter, equal to 10 l/m². A large filter area 
would be needed for the filtration of crude extract. On a small scale this could be achieved by 
exchanging the filter paper in the funnel several times. On a larger scale this would not be 
practical; even with vacuum belt filters this would be challenging. 
Plant sap was also generated by pressing. Leaves were separated into two pieces by 
removing the middle vein. One lamina was plate pressed (II.2.2) two or three times until no 
further liquid was recovered. The other lamina was extracted using a Waring blender. Up to 
90% of the fresh weight was recovered as press juice. This extract had the advantage of 
containing hardly any fibers. Analysis by ELISA showed that the extraction efficiency was low 
(8 mg/kg compared to 27 mg/kg by blender extraction, equal to 28%) so this method was not 
considered further for antibody production (see Table III-1). This low efficiency was due to 
incomplete removal of the antibody from the apoplasmic space. The plant cells were split 
open by pressing and the cytoplasmic liquid was exuded, flushing out a small amount of the 
apoplasmic antibody. Complete flushing would need a higher degree of apoplast destruction, 
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as well as higher conductivity to overcome ionic interactions between the antibody and 
apoplast components. 
Interestingly dispersion of the middle veins in the Waring blender produced an extract with a 
low TSP, as determined by SDS-PAGE, but a relatively high antibody concentration. 
Nevertheless processing only the middle veins was not an option due to the low absolute 
antibody amounts. 
Table III-1: Comparison of plant material processed by blender and plate presses, respectively. 
Harvested tobacco leaves were separated along the middle vein and extractable antibody levels were compared 
(II.4.2) for different extraction methods (II.2.2). Extraction levels at each pressing step correlated with the used 
leaf mass from the previous press step. 
Extraction level [mg/kg] 
Extraction method 
Leaf extraction #1 Leaf extraction #2 Middle vein extraction #1 
Middle vein 
extraction #2 
Blender 26.2 28.2 10.0 7.9 
First pressing 3.3 2.4   
Second pressing 7.6 7.8   
Third pressing - 4.5   
Overall pressing 7.7 7.5   
 
a b 
Figure III-1: Coomassie-stained SDS-polyacrylamide gel (a) and western blot (b) of blender extraction and 
plate pressing. 
One lamina of the leaves was processed by blender and the other lamina by pressing (II.2.2). (M – Marker; Std. –
 CHO2G12; 1 – extract of blended lamina; 2 – first press-extract of lamina; 3 – second press-extract of lamina; 4 –
 third press-extract of lamina; 5 – middle vein extracted using the Waring blender) 
III.3 2G12 expression levels 
Antibody expression levels varied in different parts of the plant. A representative amount of 
biomass (typically nine leaves) was harvested from 20 plants, and leaf material from the 
upper, middle and lower parts of each plant was separated. Fresh biomass, TSP (method 
II.4.8) and the amount of extracted antibody (method II.4.2) were compared. 
M      1       2     3       4      5 
HC 
LC 
M    Std.     1       2      3       4       5 
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Table III-2: Overview of antibody levels in upper, middle and lower leaves. 
Leaf material from 20 plants was harvested from the top, middle and bottom part, separately extracted (II.2.2) and 
analyzed regarding the 2G12 level (II.4.2) and TSP (II.4.8). Deviations from 100% are due to rounding. 
Leaf 
origin 
Expression 
level [mg/kg] 
Leaf mass 
[g] 
Extracted 
2G12 [mg] 
Relative 
biomass 
Rel. antibody 
amount 
Rel. protein 
amount 
Top 48.4 467 22.6 17% 29% 34% 
Middle 30.6 1194 36.5 43% 46% 46% 
Bottom 17.1 1139 19.5 41% 25% 21% 
Total 28.1 2800 78.6 100% 100% 100% 
Antibody levels decreased as leaves became older. The middle and lower leaves contributed 
approximately the same biomass but twice as much antibody was extracted from the middle 
leaves. The upper leaves contributed less than 20% of the biomass but contained three 
times higher expression level than the lower leaves. 
top
middle
bottom
0
10
20
30
40
50
[%
; m
g/
kg
]
Plant part
rel. biomass content [%]
rel. Ab content [%]
rel. Protein content [%]
exp. level [mg/kg]
 
Figure III-2: Biomass and antibody distribution within tobacco plants. 
Plant leaf material was processed according to II.2.2 and Ab levels analyzed by ELISA (II.4.2). 
The average antibody level was 28.1 mg/kg, but in the younger, upper leaves, this increased 
to 48.4 mg/kg. The average level needs to be used to calculate the biomass required for 
extraction to avoid non-representative calculations from specific parts of the plant. 
Biomass and antibody distribution data provided by M. Sack and Dr. T. Rademacher 
supported these findings. The biomass distribution shown in Figure III-3 indicates that upper 
leaves are smaller than middle and lower leaves, and that the stem represents the largest 
amount of unused biomass. 
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Figure III-3: Biomass distribution within a tobacco plant. 
Harvested biomass, represented by the green sectors, accumulated to 69% of the total aerial biomass. Unused 
biomass mainly consisted of the stem. (Figure provided by M. Sack) 
Figure III-4 provides an overview of antibody levels in a representative population of 
screened plants. The variations within the plant population were small, indicating a relatively 
homogeneous expression level. 
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Figure III-4: Expression level variation within a plant population. 
Expression level deviations were small, suggesting antibody levels were homogeneous throughout the T5 plant 
population. (Figure provided by M. Sack) 
III.4 Approaches for the dispersion of plant biomass 
The laboratory scale dispersion of plant material (up to 500 g leaves) was accomplished 
using a Waring Blender and a Reactron2 (2 l working volume). At the pilot scale (up to 12 kg 
leaf material), dispersion was achieved using a Reactron50 (50 l working volume) (II.2.3). 
Initially operation of the pilot dispersion unit Reactron50 was carried out with 9 kg fresh 
weight leaf mass combined with three volumes of extraction buffer. For pre-dispersion size 
reduction, the leaves were torn by hand into three pieces and filled into the vessel. To obtain 
a liquid extract, they were combined with three volumes of buffer. During dispersion, the 
following problems occurred: 
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- The layer of leaves below the anchor stirrer prevented the lid from closing 
- The non-adjustable rotation speed of the anchor stirrer (34 rpm) resulted in strong 
circular flow 
- Leaf pieces >3 cm stacked up at built-in components such as the temperature 
probe and Polytron bars, and detaching them was not possible, resulting in no 
further dispersion 
- The Polytron generator was clogged by fibrous leaf material (Figure III-5) 
- The Polytron generator inlet slots were covered by large leaves 
a b 
Figure III-5: Fibrous plant material sticking inside the stator. 
Leaf material was processed according to II.2.3. 
To facilitate dispersion, the adhering leaf fragments were removed from the built-in 
components by hand several times. Even when using leaves cut into <3 cm strips, 
orthogonally to the midrib, the throughput of the Polytron and anchor stirrer could not be 
improved. The Polytron achieved an average particle size of 6 mm, which was not small 
enough for the subsequent fine dispersion step. Fibers from the middle veins up to 4 cm in 
length still remained intact, whereas fine dispersion required a maximum input size of 3 mm 
without large fibers. Therefore, the system comprising the Polytron for pre-dispersal size 
reduction and the anchor stirrer for mixing proved to be unsuitable for the processing of leafy 
material. 
Further processing of the pretreated extract with the Megatron for fine dispersion was 
challenging. Fibers from the middle vein attached to the cutting edge of the rotor and stator 
making them blunt, resulting in inefficient disintegration. Automatic removal (self-cleaning) by 
the orthogonal movement of the cutting edge through the liquid was not taking place, and 
larger, incompletely disintegrated particles clogged the innermost chamber in the three-row 
rotor, as shown in Figure III-6. 
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a            b 
Figure III-6: Clogged rotor of the Megatron generator (a) and the particles which were found inside (b). 
Leaf material was processed according to II.2.3. The seal, shown for comparison, had a diameter of 52 mm.  
The gaps between the teeth were too small to allow passage of the particles and fibers, and 
this disrupted the sheer gap between rotor and stator resulting in a lower recirculation flow 
and lower dispersion efficiency. 
III.4.1 Optimization of RT50 Megatron and Polytron 
The fine dispersion unit Megatron was optimized in parallel with the pre-dispersion Polytron. 
To solve the problems caused by clogging, a new fine dispersion generator was designed 
(Figure III-7). Three features of the generator design were changed to incorporate a self-
cleaning effect: 
• The innermost ring of teeth was omitted to generate greater centrifugal forces in the 
innermost chamber due to the increased radius. Thus liquid and particles were 
pressed more forcefully against the rotor and stator. 
• The gaps between the teeth in the rotor and stator were enlarged to allow larger 
remaining particles and fibers passage through the generator without clogging. 
• Bevel teeth flanks were installed, at an angle that forced a small amount of liquid to 
flow tangentially over the teeth flank. Thus, attached fibers were removed and no 
longer blunted the cutting edges. 
These improvements increased throughput with water from 57 l/min to 85 l/min (an increase 
of 49%). Crude extract flow was increased from 43 l/min to 61 l/min. The new design had a 
much greater particle tolerance. Leaf fragments of up to 1 cm could be processed without 
accumulation of any plant material in the generator chamber as shown in Figure III-8. 
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Figure III-7: Improved design of the Megatron generator. 
Angled cutting edges in the rotor (blue) and stator (yellow) are shown. The flow enters the generator centrally 
from the top through the stator and exits radially by passing through the rotating teeth. (Figure provided by 
Kinematica AG) 
 
a  b 
Figure III-8: Comparison of old (a) and new (b) Megatron rotor design. 
Both pictures show the rotors directly after use without cleaning. The absence of particle clogging in the new rotor 
(b) is shown, whereas the innermost chamber of the old rotor (a) is clogged with fibers, after processing leaf 
material according to II.2.3. 
The following actions were carried out to optimize pre-dispersion: 
• The Polytron stator was removed 
• The anchor stirrer was completely removed to allow a larger-diameter knife to be 
incorporated 
• The rotor was replaced with free-rotating blades with a large diameter. The blades 
were almost rectangular, 250 mm in diameter, 2 mm thick and 5 cm wide with a 45° 
phase at the front and small wings with an angle of 10° at the rear end to facilitate the 
creation of flow. 
At 3000 rpm, the peripheral speed was equivalent to 39 m/s, similar to the 40 m/s achieved 
by the Megatron generator. In contrast to the original Polytron and anchor stirrer system, 
adequate mixing was accomplished by the blades because of the front phase and the small 
wings, which together created an upward flow orthogonal to the rotation plane, as shown in 
Figure III-9a. 
An initial trial showed strong potential for this pre-dispersion method. In the first few 
experiments, all leaf pieces were smaller (<4 mm) compared to the particles created with the 
original Polytron generator. No intact middle veins were found in the extract. However, 
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because of vibration during operation, probably caused by imbalances and bending due to 
the thin blade material, a new knife was constructed. 
This knife was similar in dimensions to the original but the thickness was increased to 5 mm 
and the rear wings were removed. Sufficient upward flow for mixing was achieved by the 45° 
phase at the cutting edge. Initially an entire batch of leaves and buffer was loaded into the 
vessel before the blades began to spin, but at high speeds leaves attached to the cutting 
edge and moved along the circular path. This caused the whole skid to vibrate when the 
blade velocity was not sufficient to shred the leaves. Two ways to reduce the vibrations were 
investigated: semi-continuous feeding of leaf material in 2 kg steps, and continuous feeding 
through a small vent in the lid, after filling the vessel with three volumes of buffer. Vibrations 
still occurred at high speed because of the imperfect balance of the rotating mass. A second-
stage of knife was therefore designed, which reduced the rotating mass by reducing the 
radius and width of the knife (Figure III-9). By doing so, semi-continuous feeding was no 
longer necessary, as vibrations no longer occurred during acceleration. However, the lower 
radius of 144 mm reduced the peripheral speed, also reducing the dispersion efficiency and 
yielding a larger final particle size. To increase the peripheral speed without vibration during 
acceleration, a new blade shape was designed. 
 
Figure III-9: First, second and third rotating knife design. 
Rotation direction was clockwise. (a) first-stage of free rotating blade; (b) second-stage of free rotating blade with 
a smaller radius and lower rotating mass (c) Third-stage dispersion blade with curved blades and increased 
radius. 
The third-stage blade combined the advantages of the earlier blades, with a thickness of 
5 mm, a 45° phase at the cutting edge, a large radius of 200 mm for high peripheral speed as 
well as a slim shape to minimize the rotating mass. Special attention was paid to the 
curvature of the cutting edge. The shape followed a hyperbolic curve: when starting from a 
radius of 27 mm at 0°, the radius increases with increasing angle up to 100 mm. The smaller 
the radius the higher is the tangential flow at the cutting edge. With this special shape 
particles were not able to attach to the blades but were removed by the tangential flow. Due 
to this self-cleaning-effect the blades stayed sharp and leaves were not moved along a 
a b c
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circular path, so vibrations were eliminated. A final maximum particle size <3 mm was 
achieved. 
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Figure III-10: Custom-made blades to replace the Polytron generator. 
The fourth-stage knife incorporated final improvements by doubling the number of cutting 
edges, decreasing the cutting angle from 45° to 30° and increasing the rotation speed to 
3600 rpm. Two knives with two blades each were mounted 10 mm apart and 90° out of 
phase. The number of blades reduced the time needed for dispersion, the blade angle and 
rotation speed were characteristic for the degree of dispersion. A final particle size <2 mm 
was achieved. Figure III-11 shows the configuration of the final pre-dispersion unit. 
a b 
Figure III-11: Fourth-stage free rotating blades were self-cleaning for optimal pre-dispersion. 
The 90° phase between knives is clearly shown. When compared with Figure III-5 no adhered fibrous particles 
were visible after processing leaf material according to II.2.3. 
By using the new fourth-generation blade for pre-dispersion it became clear that the fine 
dispersion step was no longer necessary since there was no further improvement in antibody 
extraction. Inclusion of the second dispersion step increased the yield of TSP by 10% but 
had no effect on the antibody titer. The second dispersion step was therefore omitted from 
further process development. The increase in TSP but not antibody levels could reflect the 
disruption of organelles. Chloroplasts, for example, contain large amounts of rubisco that are 
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released into the supernatant after disruption. In contrast, the antibody accumulated in the 
apoplast, which was completely disrupted by the Polytron. 
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Figure III-12: 2G12 extraction with optimized blade design. 
Leaf material was dispersed using the third (2 blades, 45° cutting edge, 3000 rpm) and fourth (4 blades, 30° 
cutting edge, 3600 rpm) cutting tool design (according to II.2.3). 
In summery the optimization of the pre-dispersion unit Polytron resulted in 73% shorter 
dispersion times (8 min Polytron instead of 15 min Polytron and 15 min Megatron, as 
required in the original configuration). Contact time with high shear forces and heat-inducing 
steps was significantly reduced, resulting in a lower stress level for the antibody. Cleaning of 
the complex Megatron machinery was also avoided, reducing the labor required to carry out 
the downstream process. 
The Megatron might still be useful for different types of plant material. When targeting the 
protein of interest into organelles like chloroplasts or the endoplasmic reticulum, greater 
shear forces are needed for disruption. Also, seed material such as maize kernels could 
benefit from Megatron dispersion (data not shown). 
To prepare for Protein A-based capture chromatography, the pH of the extract was adjusted 
to 7.50 ± 0.05 immediately after dispersion. Therefore the rotation speed of the Polytron was 
decreased to ~750 rpm to achieve homogeneous mixing. 400 mM trisodiumphosphate 
(without pH adjustment) was used as the buffer. In contrast to 1 M NaOH, peaks pH >12 
could be avoided, thus minimizing pH stress to the antibody. Approximately 2.5% (v/v) was 
added by using a peristaltic pump into the well-mixed extract. 
III.5 Approaches for fiber removal 
Dispersion of leafy biomass generated a viscous extract containing high levels of solids (20% 
w/v). The antibody was released into the supernatant during dispersion. For further 
chromatographic processing, it was necessary to remove particles from the supernatant. 
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Both centrifugation and filter presses were considered for this purpose. Centrifugation is 
often a reliable, robust and inexpensive method for laboratory-scale solids removal. Different 
types of centrifugation were investigated for larger-scale use, including separators and 
decanters (two types of continuous centrifugation suitable for liquids containing high solid 
contents), but this would require significant up-front investment for larger-scale processes 
and would be of limited use in downscaled process development. Similar problems were 
associated with filter presses so both were eliminated from the 2G12 process development. 
III.5.1 Fiber removal by custom-made filter capsules  
We next investigated dead-end filtration, which is a scalable and commercially available 
method for fiber removal. Filtration with commercial standard filter capsules as a first filtration 
step was not practical because the inlet head space was immediately clogged with filter 
cake. In cooperation with Sartorius Stedim Biotech a new filter type was developed for the 
separation of fibers. Capsules were constructed from GMP-compliant standard filter 
materials, so they could be used directly in the process scale purification of 2G12 from 
tobacco under GMP conditions. The capsules were fully disposable, so cleaning and 
validation of cleaning procedures were unnecessary. The filters were operated with a 
peristaltic pump, monitored by pressure gauge. When using dead-end filtration as a first filter 
step, special attention had to be paid to the large dead volume in the capsule to collect large 
amounts of filter cake. Initial capsules were 5” long and featured a standard Sartorius 
housing with tri-clamp fittings. The polypropylene filter material comprised outer and inner 
layers with pore sizes of 0.5 mm and 0.1 mm, respectively. The distance between core and 
housing provided space for filter cake uptake. Fibers entering the capsules were retained by 
the outer layer of filter cloth (shown in Figure III-13), forming an uncompressed filter cake. 
Smaller fibers passing the outer layer were initially retained at the inner layer, and after 
prolonged filtration they were retained by the filter cake. When the loose filter cake filled the 
whole dead space of the capsule, cake compression began to occur. The filtrate was visually 
particle free with a low viscosity and an average turbidity of 2500 NTU. 
a b 
Figure III-13: Custom made 5” pre-filter capsule. 
Tobacco extract was generated by dispersion (II.2.2). After filtration (II.2.4.1) the capsule housing was removed 
(a) and the filter cloth was unwound (b). 
To allow adequate compression of the filter cake, a pumping rate of 100 ml/min was used for 
the 10”, 20” and 30” capsules. The filter was constructed in such a way that the flow rate was 
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proportional to the capsule diameter and not its height. At this flow rate, the capacity was 10 l 
of crude extract per 10” of capsule. A faster flow resulted in lower cake compression and 
thus lower capacity. When the filter cake filled the whole housing, the flow rate must be lower 
than the volume profit caused by compression. Otherwise the pressure will increase 
immediately. 
Scale up is possible by increases in length and diameter. The successful scale up in 
diameter from to 8 cm to 19 cm resulted in a capacity increase to 30 l per 10” of capsule and 
an increase in flow rate to 250 ml/min. One RT50 run at the pilot scale could be completely 
filtered by such an up-scaled capsule, as shown in Figure III-14 c-d. On average, 5.8 kg filter 
cake could be retained in this large capsule. 
a   b   c    d 
Figure III-14: Custom pre-filter capsules. 
Leaf material was dispersed (II.2.3) and filtrated (II.2.4.1). (a) Two 30” pre-filter capsules were driven in parallel. 
(b) Capsule with removed housing. (c) Further upscale in pre-filter capsule diameter. The capsule length was 10”, 
diameter was 19 cm. (d) Up scaled capsule with removed housing. The filter cake was 5 cm in depth. 
Furthermore the materials we used were standard filter components from Sartorius Stedim 
Biotech, which are FDA approved for later production under cGMP conditions. The capsules 
were fully disposable, so no cleaning or validation was needed. Additionally all filtration 
disposables could be delivered by one supplier. Further up-scaling was not achievable during 
the course of this project. To close the gap between the capabilities of this filter and the 
requirements at production scale, a similar filter type was invented as described in III.5.2 
III.5.2 Fiber removal by bag filter 
A complementary method for particle removal was developed using bag filters. The size of 
the filter bags was 81 cm in length and 17.8 cm in diameter, offering a filter area of 0.45 m². 
The bag filters with a nominal pore size of 1.5 µm offered a filter cake capacity of more than 
15 kg at a high flow rate of 1000 ml/min. 
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Figure III-15: Bag filter housing. 
TC-adapters, manufactured by the RWTH Aachen workshop, as well as a pressure gauge and pressure release 
valve were mounted on the housing. A cage mechanically supports the filter bag inside. The bag retains the large 
particles and fibers from the crude extract. 
Approximately 15% of unfiltered material accumulated as filter cake. The filtrate turbidity of 
~3000 NTU was comparable with the performance of the pre-filter capsules developed with 
Sartorius Stedim Biotech (III.5.1). Challenges with the bag filters included the missing FDA 
approval for use under cGMP conditions and the fact that it was not fully disposable, 
resulting in labor intensive cleaning and cleaning validation. Additionally this process step is 
not completely closed, as the system has to be opened for filter bag exchange. This might be 
overcome by massive upscaling to a bag filter size which could retain the whole fiber material 
of a batch at once. 
III.6 Approaches for extract clarification 
The filtration methods, presented in III.5, yielded a fiber-free extract of low viscosity and with 
a turbidity of 2500-3000 NTU. For further chromatographic processing, the extract had to be 
clarified to prevent matrix fouling and clogging during the capture step. 
III.6.1 Extract clarification by hollow-fiber filtration 
Hollow-fiber filtration (II.2.4.2) was tested as a method to remove particles from the antibody 
extract. The module was 60 cm long with a filtration area of 0.28 m², a lumen of 1.0 mm 
diameter and a pore size of 0.45 µm. This represented the recommended parameters for 
antibody purification from cell culture fluid (GE 2007). Control of the permeate flow was also 
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recommended (GE 2007) to achieve the highest possible filtration performance. Leaf 
material was dispersed with three volumes of buffer using the RT50 (II.2.3). The crude 
extract was filtrated using the custom-made pre-filter (III.5.1) and a Sartopure PP2 5 µm 
capsule. The starting material for the hollow fiber filtration was an extract volume of 48 l. The 
filtration skid was equilibrated with extraction buffer and the recirculation tank was cooled to 
4°C. A negligible amount of 1 l of equilibration buffer remained in the pump and hollow fiber 
module to avoid air in the system. The cooled recirculation tank was filled to 12 l and 
samples were taken from the retentate and permeate at the same time and analyzed by SPR 
(II.4.1) to determine the antibody concentration. Figure III-16 shows the distribution of the 
antibody between retentate and permeate during filtration. Initially, antibody passage was 
88%, decreasing to 57% at a concentration factor of 2 (Cx = 2). At Cx = 3–5, the antibody 
concentration remained constant in the permeate and increased slightly at higher Cx. The 
relative passage of antibody in the ratio cperm/cret decreased to 25% at Cx = 3 and remained 
constant at 22% until Cx = 10. 
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Figure III-16: Hollow-fiber filtration of fiber-free extract. 
Leaf material was dispersed (II.2.3) and the extract was pre-filtered (II.2.4.1). Hollow fiber filtration was carried out 
according to II.2.4.2. Samples were analyzed by SPR (II.4.1) for antibody concentration. 
The final concentrate comprised 20% solids, representing a highly viscous and particle-rich 
feed stream. Antibody passage was most probably hindered by gel layer formation on the 
membrane. In summary, only 59% of the initial amount of antibody could be found in the 
permeate, while 41% remained in the retentate. Because of the low antibody passage 
through the membrane, clarification of pre-filtrated extract by HFF was not sufficient to be 
used in a large-scale process. Although high shear and flow rates were used in combination 
with a large pore size, controlled permeate flow and controlled TMP, HFF proved to be not a 
suitable method for plant extract clarification. Nevertheless this method was an interesting 
technique for clarification, but needed more process development which was not achievable 
within this project. 
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III.6.2 Extract clarification by depth filtration 
Fiber removal after dispersion (III.4) was achieved using the custom-made pre-filter capsule 
or bag filter, described in III.5. For further chromatographic processing total clarification was 
required to protect the capture matrix from fouling. 
Successive filtration by Sartopure PP2 filters featuring retention rates of 8 µm and 5 µm 
reduced the turbidity from ~2500 NTU to ~2200 NTU and ~1100 NTU, respectively. Filtration 
with a 5 µm filter reduced turbidity still further (50%), whereas 8 µm filtration reduced turbidity 
by only 10%. An additional filtration using a 3 µm Sartopure PP2 reduced filtrate turbidity to 
1000 NTU. Particles in the extract did not build up a filter layer, which would result in 
increased back pressure. No increase in pressure during filtration hinted at poor particle 
retention performance. Whereas the 5 µm filter performed well, the inclusion of a subsequent 
3 µm filter did not separate enough particles for significant further turbidity reduction, so this 
step was discontinued.  
Final clarification was achieved using Sartoclear capsules containing diatomaceous earth. 
Retention rates of 11, 8 and 4 µm, respectively, resulted in an early particle break through 
and consequently in a high filtrate turbidity (>800 NTU), which converged to the turbidity of 
the 5 µm filtrate. Without an increase in back pressure, particle break through indicated no 
further particle retention, thus the use of the filters listed above was also discontinued. 
The next approach for final clarification filtration consisted of three filtration steps with 
retention rates of 1.5, 1.0 and 0.3 µm nominal cutoff. Filtrate turbidity was initially <100 NTU 
when using the 1.5 µm filter, indicating high particle retention. The turbidity increased to the 
value of the unfiltered feed when the pressure drop reached 0.4 bars without a further 
increase in back pressure. The 1 µm filter reduced the turbidities of the 1.5 µm filtrate from 
500 NTU down to 20 NTU. The 1 µm Sartoclear filter acted as the main clarification step, 
resulting in the shortest filter life time of ~110 l/m². A polishing Sartoclear filter with a 
retention rate of 0.3 µm reduced the turbidity to values below 5 NTU. Furthermore the 0.3 µm 
filter acted as safe guard in case the turbidity increased at the 1 µm filter, guaranteeing a 
filtrate of constantly low turbidity. This allowed trouble free 0.2 µm inline filtration during the 
capture chromatography step described in III.7.2.3. Table III-3 provides an overview of the 
filter cascade and filter lifetimes discussed above. 
Table III-3: Capacity of different filter types used during pilot scale clarification. 
Extract for clarification (II.2.4.1) was generated by dispersion (II.2.3) and bag filtration (II.2.4.1). 
Type of filter Flux [l/h/m²] Filter capacity [l/m²] 
Sartopure PP2 8 µm 10 >360 
Sartopure PP2 5 µm 10 350 
Sartoclear 1.5 µm 100 150 
Sartoclear 1 µm 100 110 
Sartoclear 0.3 µm 100 >360 
Sartopore 2 0.45/0.2 µm 100 >400 
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The cascade discussed above was an excellent solution for laboratory and pilot scale 
clarification of the tobacco extract, but was too complex for larger scales. A reduction in the 
lifetime of the 1 µm Sartoclear filter was an excellent compromise for the reduction of filter 
steps. The Sartopure PP2, with retention rates of 5 µm and 8 µm, and the Sartoclear 1.5 µm, 
were removed. The Sartoclear 1 µm and 0.3 µm were scaled up from 0.22 m² to 1.8 m², an 
8.2-fold increase. Because of pump limitations the volumetric flow rate was not proportionally 
increased, leading to reduced flow per area and time. This lower flux did not negatively 
influence the retention rates and life times. All filter lifetimes were within acceptable ranges 
and were determined as shown in Table III-4: 
Table III-4: Capacity of filter types used during large scale production. 
Extract for clarification (II.2.4.1) was generated by dispersion (II.2.3) and bag filtration (II.2.4.1). 
Type of filter Flux [l/h/m²] Filter capacity [l/m²] 
Sartoclear 1 µm 25 61 
Sartoclear 0.3 µm 25 >440 
Sartopore 2 0.45/0.2 µm 40 400 
In summary, total clarification could be achieved by successive filtration using Sartoclear 
filters based on diatomaceous earth, with retention rates of 1 and 0.3 µm. The following 
0.2 µm filtration step guaranteed a maximum particle size <0.2 µm to protect the subsequent 
chromatography steps from fouling. The final extract was clear, stable overnight (if needed), 
without detectable browning reactions and thus ready for chromatography.  
III.7 Approaches for capturing 2G12 from clarified tobacco extract 
The filtration described in III.5 for fiber removal and in III.6.2 for clarification using Sartoclear 
depth filters resulted in a fiber- and particle-free extract. This extract was subjected to further 
0.2 µm inline filtration before introduction into the chromatography capture device (the term 
‘clarified’ in this thesis includes the 0.2 µm filtration step unless otherwise stated). Different 
approaches were investigated to concentrate and purify the monoclonal antibody from the 
clarified tobacco extract. This included affinity and non-affinity packed bed chromatography 
as well as affinity membrane chromatography in tangential and orthogonal flow modes. 
III.7.1 Capture by packed-bed chromatography 
III.7.1.1 Capture on a Protein A column 
Antibody capture from the clarified extract was initially tested using a XK16 Protein A column, 
with a bed height of 12.5 cm and a flow rate of 300 cm/h. We loaded 78 column volumes 
(CV) of extract onto the column as described in II.2.5.3. A chromatogram for process 
visualization is shown in Figure III-17.  
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Figure III-17: Antibody capture on a Protein A column. 
Column parameters: XK16, 12 cm bed height, 300 cm/h. (Curves: blue – UV280) 78 CV of clarified extract 
(according to II.2.2 and II.2.4.1) were applied to the equilibrated column. After column washing to remove 
impurities, elution was triggered by pH shift (II.2.5.3). 
In the flow-through fraction, no antibody was detected by SPR (II.4.1). A recovery of 70% 
determined by SPR was achieved in the elution fractions. In this experiment, a binding 
capacity of 1 mg/ml was achieved using only 5% of the binding capacity indicated by the 
manufacturer. When using a Protein A column to capture low titers of antibody from tobacco 
extracts on a large scale, two extremes can be envisaged: 
• Fast processing of tobacco extract: For processing plant extracts rapidly on a large 
scale, it would be necessary to use high volumetric flow rates. This would require a 
large column diameter in combination with a reasonable bed height for contact time 
would result in large column volumes. By doing so only a small percentage of the 
available binding capacity would be used, resulting in an oversized column. Tobacco 
extract would lead to reduced column and ligand lifetime because of its complex 
nature. Because Protein A is a biologically active ligand, harsh cleaning procedures 
(such 1 M NaOH) would not be appropriate. 
• Full capacity exploitation: Using an adequate bed volume to achieve the desired 
capacity would reduce volumetric flow, resulting in a long process time. This could 
encourage unpredictable reactions to occur during extract storage, resulting in a non-
uniform product. 
As result, capture on a Protein A column was not the best solution for 2G12 present at low 
concentrations in complex tobacco extracts. 
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III.7.1.2 Capture on a non-affinity column 
Non-affinity chromatography allows the use of rigorous CIP procedures in contrast to 
Protein A. Additionally the resins are less expensive, and thus more suitable for the “dirty job” 
of extracting antibodies from complex plant extracts. 
A “normal” ion exchange resin was unsuitable due to high conductivity of the loading 
material, but Capto-MMC offered cation exchange characteristics and salt-tolerance. The 
extraction buffer for this capture step was 50 mM NaH2PO4 and 50 mM NaCl, pH 6.0. The 
dynamic binding capacity was shown to be 50 CV at 10% antibody break through, equal to 
0.3 mgAb/ml (Equation II-6). This low capacity was caused by the high TSP contained in the 
extract and the nonspecific binding mechanism. All positively charged proteins and other 
substances in the total extract bound to the matrix, thus covering almost all binding sites. 
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Figure III-18: Break through curve of tobacco extract applied to Capto MMC resin. 
Extract was generated according to II.2.2. The antibody concentration in the flow-through fraction (II.2.5.1) was 
analyzed by SPR (II.4.1). 
To minimize the loss of antibody during loading, the extract volume applied to the column 
should be limited to 30 CV, where the flow-through concentration of antibody is <1.5%. An 
up-scaled capture step would result in a 20 l column for processing 600 l clarified extract in a 
later GMP-compliant process. 
Under these conditions, a capture step based on affinity capture would be preferred to a non-
affinity capture step. For mammalian cell culture, a non-affinity capture step might be optimal 
when using protein-free fermentation media and producing secreted antibodies. There the 
antibody contained in the supernatant would already have a significantly high purity. Thus 
higher binding capacities would be achieved because of the absence of binding competitors. 
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III.7.2 Capture on affinity membranes  
III.7.2.1 Capture by the tangential flow affinity membrane technique 
Tangential flow membrane modules are particle tolerant, facilitating the capture of proteins 
from difficult or non-filterable feed streams. As shown in Figure III-19, the membrane is 
wound around a core and flow is directed tangentially over the membrane. Because of the 
reduced contact intensity, membrane loading is carried out predominantly in recirculation 
mode. Different spacer materials between the membrane layers enable particles to pass 
through the module without clogging. We were therefore able to test the module with 
unclarified feeds. 
 
Figure III-19: Flow direction of Sartobind Direct. 
The membrane is wound around a core, and flow is tangential over the membrane. Spacers between the 
membrane layers enable particles to pass through the module. (Provided by Sartorius Stedim Biotech) 
The particle size in the crude extract after dispersal was ≤2 mm, and increasing the dispersal 
time did not reduce the size further (data not shown). 
a      b 
Figure III-20: Particle size determination in crude extracts after dispersal with RT2. 
(a) Particles after 5 min dispersal in the Megatron unit (II.2.2). A 1.7 mm fiber and epidermis tissue including 
stomata can be recognized. (b) Remaining fiber particles after 10 min dispersal, with a size of ~1 mm. 
For optimal visual evaluation, the spacer layer in the Sartobind Direct module was simulated 
by sandwiching spacer cloth between two acrylic plates, allowing an orthogonal view of the 
flow distribution within the spacer material. Crude plant extract was pumped through the 
spacer material, followed by washing solutions. Figure III-21a shows the Sartobind Direct 
spacer material with a pore size of 5 x 5 mm, the largest pore size available. Figure III-21c 
shows the heterogeneous flow distribution through the spacer after applying washing 
solution. The heterogeneous flow would not utilize the total membrane area, thus reducing 
RESULTS AND DISCUSSION 
 46 
the binding capacity of the module. Additionally, cleaning to remove fibers would be 
impossible resulting in strong membrane fouling. Capturing antibodies from untreated crude 
tobacco extract was therefore not possible using Sartobind Direct due to the nature of the 
tobacco extract, which contained high amount of fiber and the large size of the fibers. 
a b c 
Figure III-21: Sartobind Direct spacer material tested for particle tolerance. 
Crude extract was generated according to II.2.2. (a) Spacer material before application of crude extract. (b) 
Heterogeneous flow was already recognizable during extract loading. (c) After washing, clear flow paths were 
visible, resulting in unused membrane area in the Sartobind Direct module. 
Fleece, as another type of spacer material with very narrow pores (<100 µm), was also 
tested with tobacco extract, in this case pre-filtered using custom-made capsules (III.5.1). 
Figure III-22 demonstrates the fine particle tolerance of the fine spacer fleece. After washing, 
no fine particles remained in the spacer. Capture of pre-filtered but non-clarified extract by 
Sartobind direct would not be hindered by the spacer material. 
a   b 
Figure III-22: Sartobind Direct spacer material tested with pre-filtered plant extract. 
Extract was generated and pre-filtered according to II.2.2 and II.2.4.1, respectively. (a) Pre-filtered extract was 
loaded onto fine filter fleece. (b) Fleece spacer after washing. 
For capacity testing, 2G12 purified from tobacco extract by Protein A chromatography was 
diluted to a concentration of 8 mg/l in PBS, reflecting the concentration in the tobacco 
extract, and 800 ml of this solution was circulated through a Sartobind Direct containing a 
Protein A membrane. After 2 h of circulation, 63% of the antibody remained in the 
supernatant (Figure III-23). This was equal to a dynamic binding capacity of 
0.95 mg2G12/mlmembrane (Equation II-6). This represents only 38% of the dynamic capacity of a 
Protein A MA 75 (III.7.2.2). Both modules employed the same type of membrane but differed 
in their inflow characteristics. 
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Figure III-23: Sartobind Direct capacity test with 2G12. 
Antibody from tobacco was purified according to II.2.2, II.2.4.1 and II.2.5.3. Protein A column eluate was diluted 
with 1x PBS to c0 = 8 µg/ml and circulated through the Protein A Sartobind Direct module. Antibody concentration 
was determined by SPR (II.4.1). 
The low capacity of the Sartobind Direct reflects the tangential flow characteristics inside the 
module. Because of the low antibody concentration in the mobile phase, the concentration 
gradient was not high enough to let the antibody diffuse into the membrane and bind there. 
Therefore Sartobind Direct was not suitable for antibody capture at the low antibody 
concentrations anticipated. 
III.7.2.2 Capture on a normal flow affinity membrane adsorber 
In contrast to the Sartobind Direct (III.7.2.1) in a “normal” MA the flow is directed orthogonally 
to the membrane. Thus liquid phase completely passed the membrane. 
MAs were tested at the laboratory scale for suitability. A Protein A MA 75 with a membrane 
volume of 2.1 ml was initially loaded with Protein A-purified plant-derived antibody diluted in 
PBS (equal to Sartobind Direct testing III.7.2.1) and then with clarified tobacco extract, both 
at a flow rate of 7.5 ml/min. The break through curve for purified antibody is shown in Figure 
III-24. The dynamic binding capacities at 10% and 5% break through were 2.5 mg/ml and 
2.3 mg/ml (Equation II-6), respectively. The shape of the break through curve indicated 
excellent flow and binding characteristics. 
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Figure III-24: MA 75 capacity determination with purified plant-derived antibody 2G12. 
Antibody from tobacco was purified according to II.2.2, II.2.4.1 and II.2.5.3. Protein A column eluate was diluted 
with 1x PBS to c0 = 8 µg/ml and loaded onto the Protein A MA 75 (II.2.5.3). Antibody concentration was 
determined by SPR (II.4.1). 
This result was reproduced when using clarified tobacco extract as the loading material. 
Figure III-25 shows the break through behavior of MA 75. The dynamic capacity at 5% break 
through was with 2.3 mg/ml (Equation II-6), the same as the purified plant-derived antibody, 
although 10% break through could not be achieved due to sample volume limitations. 
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Figure III-25: MA 75 capacity determination with clarified tobacco extract. 
Clarified extract was generated according to II.2.2 and II.2.4.1 and was loaded onto Protein A MA 75 (II.2.5.3). 
Antibody concentrations were determined by II.4.1. 
The MA showed quantitative binding of the antibody, and thus represents an ideal tool to 
capture antibody from clarified tobacco extract at high flow rates. 
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III.7.2.3 Pilot-scale antibody capture 
MAs were most appropriate tools for antibody capture from clarified tobacco extract, and up-
scaling was achieved by increasing the membrane volume by factor 74 from 2.1 ml to 
156 ml. A comparison between the laboratory-scale and pilot-scale MAs is shown in Figure 
III-26. 
 
Figure III-26: Laboratory (left) and pilot scale (right) MAs. 
The small scale unit was connected by Luer-lock-connectors. The pilot scale unit was connected by 25 mm tri-
clamp connectors. 
A flow rate of 20 l/h resulted in a contact time of 28 s. Figure III-27 shows the antibody 
concentration curve in the flow-through during a capacity test. A sharp increase in the 
amount of antibody in the flow-through indicated appropriate flow distribution without 
channeling. A dynamic binding capacity of 2.1 mg/ml at 10% break through was determined 
using Equation II-6. 
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Figure III-27: Pilot-scale capture of recombinant antibody 2G12 from clarified tobacco extract. 
Clarified extract was generated according to II.2.3 and II.2.4.1 and was loaded onto pilot scale Protein A MA 
(II.2.5.3). Antibody concentrations were determined by II.4.1. 
The chromatogram of an automated capture run is shown in Figure III-28. After equilibration, 
the extract was applied to the MA, followed by high-conductivity wash buffer. A lower 
conductivity buffer was applied in the next wash step, and elution was initiated with a pH 
switch from 7.5 to 3.2 (method shown in VII.4.1). 
RESULTS AND DISCUSSION 
 50 
0.0
1.0
2.0
3.0
AU
0.0
10.0
20.0
30.0
40.0
mS/cm
2.0
4.0
6.0
8.0
pH
0.0 10.0 20.0 30.0 40.0 50.0 60.0 l  
Figure III-28: Chromatogram of pilot-scale MA capacity test. 
(Curves: blue - UV280; gray - pH value; brown - conductivity). 50 l of clarified extract (to II.2.3 and II.2.4.1) were 
applied to pilot scale MA (II.2.5.3). Equilibration was followed by loading, two-step washing and elution with 
buffer C. 
The scale-up to pilot scale proved to be successful, as shown by the matching characteristics 
in the break through curve and dynamic binding capacity. Additionally, process parameters 
such as washing and elution volumes were directly scalable. An elution volume of three 
membrane volumes equated to ~470 ml at the pilot scale. 
Figure III-29 shows an SDS-polyacrylamide gel representing a purification process. Lanes 2–
5 show the plant extract at different process steps. An average antibody concentration of 
8 µg/ml was detected by SPR in the clarified extract immediately before capture 
chromatography. In the flow-through of the capture step (lane 5) no antibody could be 
detected by western blotting or SPR (data not shown). The wash fraction (lane 6) contained 
almost no plant proteins or target antibody. Elution (lanes 7–9) yielded 2G12 with an average 
recovery of 80%. SDS-PAGE confirmed high purity and minimal degradation compared to 
CHO2G12 (lane 10). 
 
Figure III-29: SDS-PAGE of intermediate samples taken at different process steps. 
Process consisted of dispersion (II.2.3) and clarification (II.2.4.1), followed by antibody capture on a Protein A 
pilot-scale MA (II.2.5.3). SDS-PAGE was carried out according to II.4.3. (1 – Marker; 2 – after dispersion; 3 – after 
pH-shift; 4 – after filtration; 5 – chromatography flow-through; 6 – wash; 7 – elution fraction 1; 8 – elution fraction 1 
diluted 1:10; 9 – elution fraction 2; 10 – CHO2G12). 
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The reproducibility of the capture method was tested in several purification runs, controlled 
by an automated method for the BioProcess controller skid (method is visible in VII.4.2). Six 
eluates from individual capture runs are shown in Figure III-30 and indicate high 
reproducibility even in large-scale processes when capturing antibody from 50 l clarified 
extract. No differences in the band pattern were visible in the eluates. 
 
Figure III-30: SDS-PAGE showing elution fractions from six capture runs of the Protein A MA. 
Tobacco was processed by dispersion (II.2.3), clarification (II.2.4.1) and antibody capture on a Protein A pilot-
scale MA (II.2.5.3). SDS-PAGE was carried out according to II.4.3. (1+10 – marker; 2+9 – CHO2G12; 3-8 – six 
Protein A MA eluates of SR-12G12) 
Capture chromatography using a MA proved to be a robust unit operation. The UV280 signals 
from six elution profiles were compared and are documented in Figure III-31. The elution 
fraction size was constant with three MV. 
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Figure III-31: Comparison of six different MA elution peaks at the pilot scale. 
(Curves: gray – pH; colored curves – elution fractions 1–6) Extract was generated according to II.2.3, II.2.4.1  and 
applied to the MA (II.2.5.3). Elution of the bound antibody was initiated by a shift to pH 3.2, represented by the 
gray line. The peak height depended on the loaded volume. Elution profiles correspond to the six fractions in 
Figure III-30. 
The pilot-scale MA achieved reproducible and predictable results, and seemed perfectly 
suitable for the capture of low-titer antibodies in complex feed streams in a short time. 
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III.8 Intermediate purification 
A second chromatography step was needed to remove process- and product-related 
impurities such as DNA, dimers, aggregates and degradation products (Fahrner et al. 2001). 
The most promising chromatography approaches were investigated, i.e. using Capto adhere 
and ceramic HA. Ceramic HA in widely used as an intermediate purification step in antibody 
production, whereas Capto adhere was specially developed as a polishing matrix for 
removing aggregates. It replaces anion exchange and hydrophobic interaction 
chromatography in a single step.  
III.8.1 Intermediate purification by Capto adhere 
Capto adhere was used to separate aggregates from single antibodies in the Protein A 
eluate. The medium was used in flow-through mode, since aggregates are more hydrophobic 
than single antibody molecules and thus bind more strongly to the stationary phase. DNA 
also offers a high affinity to the matrix because of their negative charge. Non-aggregated 
single antibody molecules did not bind to the matrix under our experimental conditions. 
Loading and flow-through material were analyzed by analytical gel filtration (II.4.5) to 
determine the titer of assembled antibodies. The loading material comprised 95% assembled 
antibody and this increased to 97% in the flow-through fraction. The gel filtration of 2G12 
process intermediates before and after Capto adhere chromatography is shown in Figure 
III-32, including the elution times. 
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Figure III-32: Analytical SEC of Capto adhere loading material and Capto adhere flow-through. 
(Curves: blue – loading material, red – flow-through) Load material was generated by extraction (II.2.3), filtration 
(II.2.4.1) and capture chromatography (II.2.5.3) before being applied to Capto adhere (II.2.5.2) column. Dilution 
effects in the column caused a lower peak maximum in the flow-through. 
Capto adhere successfully increased the proportion of assembled antibody in the flow-
through fraction, but DNA levels could not be determined with in-house methods because the 
levels were already so low in the Protein A eluate. 
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III.8.2 Intermediate purification by ceramic hydroxyapatite 
Ceramic HA was used to separate 2G12 dimers and higher aggregates as well as antibody 
degradation products by binding all components and separating them by selective elution. 
DNA was most likely to be eliminated by ceramic HA due to its very strong ionic interactions 
with the resin, but assays with higher sensitivity than those available in-house would be 
necessary to confirm this. 
Separation of aggregates and degradation products was traced by analytical SEC (II.4.5). As 
stated above, the loading material comprised 95% assembled antibody and this could be 
increased to 99.9% in fractions 4–8 (shown in Figure III-33).  
The Protein A eluate was neutralized to pH 6.5, the lower limit for the long-term pH-stability 
of HA. Numerous experiments to determine the optimal elution conditions in NaCl and 
phosphate gradients resulted in the following purification setup: 
• Equilibration in 5 mM phosphate buffer, pH 6.5 
• Loading of the neutralized process intermediate 
• Washing with 5 mM phosphate buffer, pH 6.5 
• Washing with 5 mM phosphate buffer, pH 6.5 and 380 mM NaCl (removal of 
degradation products) 
• Elution with 5 mM phosphate buffer, pH 6.5 and 860 mM NaCl (elution of monomeric 
2G12) 
• CIP with 400 mM Na3PO4, pH 12 (removal of aggregates and DNA) 
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Figure III-33: Process intermediate purification step with HA. 
(Curves: blue – UV280; brown – conductivity; red – fractionation) Load material was generated by extraction 
(II.2.3), filtration (II.2.4.1) and capture chromatography (II.2.5.3) before being applied to HA (II.2.5.4) column. After 
equilibration and loading, washing with 380 mM NaCl in fractions 1-3. Increase of NaCl concentration to 860 mM 
triggered elution of the antibody in fractions 4-8. CIP with 2 M NaCl happened in fractions 9-12. Additional CIP 
was achieved using 500 mM NaH2PO4 pH 6.5 in fraction 13 and 400 mM Na3PO4 pH 12. 
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Splitting the CIP into several steps (2 M NaCl, 500 mM phosphate pH 6.5 and 400 mM 
Na3PO4 pH 12) as shown in Figure III-33 enabled a more detailed analysis of the separated 
impurities. 
The total recovery of antibody as determined by SPR (II.4.1) was 92% in the flow-through 
and fractions 1–14, whereas no antibody was detected in the flow-through. About 87% of the 
loaded antibody could be detected in elution fractions 4–8, whereas 2% of antibody was 
eluted with the 2 M NaCl in phosphate buffer, as well as an additional 2% in the high-
phosphate CIP fraction. In Figure III-34, the assembled antibody ratio of the Protein A 
intermediate, HA elution and CIP fractions are compared after analysis by analytical SEC 
(II.4.5). Fractions 4–7 contained 99.9% single assembled antibody. These fractions were 
suitable for use in the subsequent process steps. Fraction 10 contained eliminated 
impurities, consisting of 55% dimers. Monomer fraction 5 and dimer fraction 10 were further 
analyzed in vitro in a virus inactivation assay, whose results are described in III.13.8. SPR 
(II.4.1) revealed no loss of activity in fractions 4–8 compared to the Protein A intermediate. 
0.0
20.0
40.0
60.0
80.0
mAU
0.0
20.0
40.0
60.0
80.0
mAU
0.0 5.0 10.0 15.0 ml  
Figure III-34: Analytical SEC of HA loading material (blue solid line), HA eluate (red lines) and HA CIP 
fraction (green line). 
Antibody samples were generated by extraction (II.2.3), filtration (II.2.4.1), Protein A capture chromatography 
(II.2.5.3) and HA intermediate purification (II.2.5.4). Fraction names correspond to those in Figure III-33. The 
monomer peak appeared at retention volume of 11.7 ml, while other peaks correspond to the 3% higher 
aggregates and 2% smaller impurities. The monomer component was 99.9% in the eluate. Fraction 10 consisted 
of 55% dimers and 45% monomers. 
Because of the strong and complex ionic interaction characteristics in the resin, it was not 
possible to obtain a sharp elution peak <2 CVs. High conductivities would be required to 
achieve such a peak, which would result in the co-elution of aggregates in the monomer 
fraction. To achieve a monomeric antibody fraction after HA purification, the elution peak 
spanning ~9 CVs was still within the acceptable range. Subsequent volume reduction could 
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Fraction 10 
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be achieved by ultrafiltration as described in III.10. The mean elution concentration was 
0.55 mg/ml. 
Ceramic HA proved to be highly effective for the intermediate purification of 2G12. 
Aggregates and degradation products were significantly reduced, thus increasing the 
percentage of monomeric antibody to 99.9%. Impurities were not detectable by silver staining 
or mass spectroscopy (see III.13.4). Because of its superior performance, ceramic HA was 
preferable to Capto adhere for implementation in the purification process. 
III.9 Polishing for virus reduction 
The eluate from the ceramic HA intermediate purification step (III.8.2) was fed into a virus 
filtration step, removing virus particles >20 nm. The operating pressure was 2.5 bars, 
resulting in a flow of ~230 ml/min using a Virosart CPV capsule with 0.2 m² filter area. The 
lifetime of this capsule was >45 l/m², indicating optimal sample preparation during the 
preceding process steps. Measurements of the absolute amount of antibody by SPR (II.4.1) 
revealed a recovery of 95%. This is an excellent result considering the antibody is 4–5 nm, 
which can be retained relatively easily by such a membrane. Additionally dilution effects 
during flushing of the capsules resulted in a final antibody concentration of 0.48 mg/ml. In 
summary, virus filtration proved to be an integral tool for 2G12 purification from tobacco. 
III.10 Ultrafiltration and diafiltration 
The virus filtered antibody (III.9) required a concentration and buffer exchange step for 
formulation. Pre-concentration, diafiltration and final concentration were carried out as 
described in II.2.7. 
Pre-concentration was carried out using a Sartoflow Alpha cross flow skid combined with a 
0.1 m² Hydrosart cassette for minimal protein adsorption. The 30 kDa NMWCO guaranteed 
concentration of the antibody with minimal losses, hence 99% of the antibody was recovered 
as determined by SPR (II.4.1). The concentration factor was 12.2, increasing the antibody 
concentration to 6.0 mg/ml. The concentration by CFF using Hydrosart 30 kDa cassettes 
proved to be an ideal unit operation to reduce large volumes for the next process step. In the 
2G12 process, a smaller volume was required than achievable with the Sartoflow Alpha 
because of the ~300 ml dead volume. 
Therefore, a Vivaflow 200 CFF module was used, since this contained a 30 kDa NMWCO 
Hydrosart membrane, analogous to the pre-concentration step. During diafiltration, the 
volume of separated permeate was replaced in the retentate. In total, seven retentate 
volumes were replaced by diafiltration solution (0.9% NaCl). Changes in the retentate flow 
were not visible. In the subsequent concentration step, there was an increase in turbidity, 
indicating that the limit of 2G12 stability and solubility at high concentrations had been 
exceeded. Concentration continued until a final volume of 140 ml was achieved, 
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concentrating the antibody solution by a factor of 5.7. The final 0.2 µm filtration confirmed the 
stability limits due to the low sterile filter capacity; 77% of the antibody after pre-concentration 
could be recovered in the final bulk by SPR (II.4.1). The final concentration was 30.1 mg/ml 
as coincidentally determined by SPR, Bradford, UV280 and gravimetrical measurements 
(II.4.1, II.4.8). 
III.11 Stability results 
Antibody stability was investigated under virus-inactivating conditions. The eluate from the 
Protein A MA was stored for 4 h at RT before neutralization from pH 3.6 to 6.5. A significant 
increase in the dimer ratio, from 1.3% to 3.3%, was observed by analytical SEC (II.4.5). The 
concentration and activity, as determined by SPR (II.4.1), were not significantly affected by 
this treatment. Thus a hold step at low pH for virus inactivation would be feasible within the 
process. 
The second hold step was investigated after a pH shift into the mild acidic range (pH 6.5). 
The Protein A eluate was stored at either -80°C or 4°C for 8 weeks, or at RT for 4 weeks. 
Storage at -80°C resulted in no significant change in the eluate composition. Storage at 4°C 
or RT resulted in a significant increase in free LC and HC dimers, as shown in Figure III-35. 
Under these storage conditions, a small proportion of the 2G12 molecules released their 
LCs, whereas the HCs remained as stable dimers, resulting in an increase in the abundance 
of single LC and HC dimers without increasing the availability of single HCs. 
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Figure III-35: Analytical gel filtration chromatogram of the Protein A eluate under different storage 
conditions. 
(Curves: blue – immediately after processing; red – storage at -80°C; green – storage at 4°C; violet – storage at 
RT). Antibody samples were generated by extraction (II.2.3), filtration (II.2.4.1) and Protein A capture 
chromatography (II.2.5.3). The retention volumes of 10.4, 11.8, 13.1, 14.4 and 15.9 ml correspond to higher 
aggregates, assembled antibody, HC dimer, single HC and single LC, respectively. 
The relative proportion of assembled antibody decreased as the storage temperature 
increased from -80°C through 4°C to RT, as indicated in Figure III-36. The relative proportion 
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of single HCs remained constant, while the relative proportion of the LC and (HC)2 species 
increased. 
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Figure III-36: Content of assembled antibody in the Protein A eluate under different storage conditions. 
Antibody samples were generated by extraction (II.2.3), filtration (II.2.4.1) and Protein A capture chromatography 
(II.2.5.3). (reference – Ab immediately after purification, -80°C – storage at -80°C, 4°C – storage at 4°C, RT – 
storage at room temperature) 
In vitro activity measurements by SPR (II.4.1) showed increases from 88% to 101% and 
106% after storage at -80°C and 4°C, respectively, in comparison to the CHO-derived 
counterpart. Storage at RT increased activity to 130% relative to the 2G12CHO. Any increase 
in activity during storage might reflect refolding after low pH-elution from the affinity 
chromatography step (Vermeer and Norde 2000). The initial activity of 88% reflects the part-
reversible miss-folding of some antibody molecules, which could refold to increase overall 
activity. Additionally, Calarese et al. (2003) reported binding between the domain-shifted VH 
regions of 2G12. An increase in binding activity might reflect this exceptional feature of 
2G12, because two (HC)2 fragments as detected in analytical SEC experiments would be 
able to bind each gp120 antigen. The concentration during storage was constant at -80°C 
and 4°C. Storage at RT resulted in 25% loss of intact assembled antibody. In summary, 
storage at 4°C is acceptable in the short term (<3 days), but storage at -80°C is necessary 
for the long term conservation of 2G12 structure and activity. Freezing and thawing did not 
affect the antibody in a significant way. RT storage is not recommended. 
 
 
 
RESULTS AND DISCUSSION 
 58 
III.12 Production of clinical-grade material from 216 kg of tobacco leaves 
The final stage of process development was up-scaling from pilot to production scale, 
enabling the production of clinical-grade material for preclinical testing and clinical phase I 
trials. 
Several large-scale purifications were carried out, using up to 240 kg of leaf material and 
960 l of crude extract. A flow diagram is provided in Figure III-37. Some details of the 
process were modified to increase the throughput, especially in the filtration and capture 
chromatography steps. The processes were driven in three 12 h shifts, with five operators 
per shift. All steps were carried out in closed systems wherever possible. Intermediates were 
cooled in bags, avoiding the exposure of plant extracts with the environment. The following 
results describe the final production batch, which was used to generate clinical-grade 
material to initiate a preclinical testing phase, but they are also representative for the 
engineering batches produced in previous runs to verify the entire process. 
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Figure III-37: Flow diagram of the production-scale process. 
We processed 216 kg tobacco leaves in 36 h as a continuous flow. Discontinuous harvest and dispersion (II.2.3) 
were followed by filtration (II.2.4.1) (permanent flow, covering bag filtration as well as 1 µm and 0.3 µm filtration 
with Sartoclear 12” modules) and chromatography (II.2.5.3) in a quasi-continuous mode. Two MAs were driven in 
parallel. One was fed with clarified extract by the quattro flow pump, while the other MA was washed, eluted, 
cleaned and equilibrated by the BioProcess controller. The eluates of the chromatography cycles were collected 
in bottles, neutralized and pooled before 0.2 µm filtration. Intermediate purification used a ceramic HA column 
(II.2.5.4), followed by virus filtration (II.2.6) for polishing. Pre-concentration, diafiltration and final concentration 
(II.2.7) served for buffer exchange and provided 2G12 at the correct concentration for final formulation. 
We collected 12 kg of tobacco leaf biomass per dispersion run, making 18 runs in total. After 
inserting the material into the dispersion vessel, buffer was added using a transfer pump. 
Parameters for discontinuous dispersion were kept constant, 8 min at 3600 rpm. The pH shift 
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was performed by adding buffer H to the crude extract in the Applicon bioreactor. 18 cycles 
of RT50 dispersion created 880 l of crude extract for filtration. The MAs used for 
chromatography set a flow rate limit of 500 ml/min. Therefore, the filtration speed of the bag 
filter was ~600 ml/min, because 15% of unfiltered material remained as filter cake. The 
filtrate was cooled in an intermediate bag to <10°C. Clarification was achieved using a 
Sartoclear 1 µm filter (12” module, filter area 1.8 m²), followed by a Sartoclear 0.3 µm of the 
same module size. The filtration was performed in continuous mode. Filters were driven up to 
2 bars, except when turbidities exceeded 300 NTU and 10 NTU for the 1 µm and 0.3 µm 
Sartoclear filters, respectively. In this large-scale production process, the bag filter and 
Sartoclear 1 µm were exchanged seven and six times, respectively. The Sartoclear 0.3 µm 
was not exchanged because the excellent performance of the 1 µm filter made this 
unnecessary. Filter lifetimes were 100 l crude extract per filter bag, 61 l/m² (110 l/module) for 
the Sartoclear 1 µm and >440 l/m² (>800 l/module) for the Sartoclear 0.3 µm. In total, 880 l 
crude extract was processed, resulting in 130 l of filter cake and 750 l of clarified extract. 
Capture chromatography was performed in quasi-continuous manner. Two MAs (156 ml 
membrane volume) were driven in parallel. While the first was loaded with clarified plant 
extract by a quattro flow pump, the second was washed, eluted, cleaned and equilibrated by 
the BioProcess controller, and vice versa. The BioProcess control method is shown in 
appendix VII.4.2. Alternation between the MAs was achieved by two four-way valves 
connected to both of the MAs as well as BioProcess controller and quattro flow pump, as 
shown in Figure III-37. By using four-way valves, disadvantageous dead volume could be 
avoided, and 750 l of clarified extract was processed in 15 chromatography runs, 50 l each. 
0.2 µm filtration to remove particles was performed inline to the MAs with Sartopore2 filters. 
The eluates from the MAs were collected in bottles and neutralized. Table III-5 shows the 
buffer volumes needed to process the large amounts of biomass. In total, almost 2.5 m³ of 
fluids were processed, excluding RO-water for material cleaning. All buffers were prepared 
under GMP conditions and filled into closed bags. 
Table III-5: Buffer volumes for large scale production. 
Processing included extraction (II.2.3), filtration (II.2.4.1) and capture chromatography (II.2.5.3). 
Type of buffer Purpose Applied volume [l] 
RO water Filter flushing and cleaning 1000 
Buffer A Extraction, MA equilibration, MA wash 900 
Buffer B MA wash 200 
Buffer C MA elution 100 
Buffer D MA CIP 100 
Buffer E MA storage 20 
Buffer F BioProcess CIP 20 
Buffer G BioProcess storage 20 
Buffer H Crude extract pH shift 20 
Eluates from the 15 MA cycles amounted to 4400 ml total, containing 4.9 g of recombinant 
antibody 2G12 at a concentration of ~1100 mg/l. This reflected a chromatographic recovery 
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rate of 79% in the eluate fraction. Additional small amounts of antibody were found in the 
tailing fractions. The collected antibody showed the typical characteristics of plant-derived 
2G12 as found in small-scale experiments: the assembled antibody represented >95% of the 
total (determined by II.4.5) (shown in Figure III-38) with an activity of 93 % (II.4.1) compared 
to CHO2G12. 
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Figure III-38: UV280 signal of an analytical gel filtration of 15 MA eluates. 
Individual antibody elution samples were generated by extraction (II.2.3), filtration (II.2.4.1) and Protein A capture 
chromatography (II.2.5.3). The assembled monomeric antibody represents >95% of the total eluates. The 
superimposed curve profiles confirm the process was reproducible and there was no fluctuation of product 
characteristics. 
Intermediate purification of the pooled Protein A eluates was carried out using a 1100 ml 
ceramic HA column (10 cm diameter) at a flow rate of 150 cm/h, resulting in a contact time of 
5.5 minutes (II.2.5.4). Intermediate purification was carried out as described in III.8.2, 
resulting in 95% recovery of the assembled antibody. In total, 4.7 g of monoclonal antibody in 
the eluate (9.0 l) could be purified to remove HCP (data not shown), DNA (see III.13.3), 
aggregates and degradation products (see III.13.1). CIP was performed only by buffer H to 
minimize buffer consumption. Thus the removed dimers could not be directly determined 
because of the denaturizing conditions in the CIP fraction. 
For virus safety, HA-purified antibody was passed through a Virosart CPV filter. The volume 
was increased to 9.75 l due to dilution effects. Over 95% of the antibody was recovered in 
this step (determined by SPR (II.4.1)), representing a total yield of 4.6 g. No blocking of the 
virus membrane was observed, indicating a high quality upstream process train. 
Pre-concentration using a 30 kDa Hydrosart CFF cassette for volume reduction resulted in a 
very high recovery of 99% (determined by SPR (II.4.1)), indicating a tightly-controlled 
process. The liquid containing 4.6 g 2G12 was concentrated from 9.75 l to 0.8 l. Buffer 
exchange to 0.9% NaCl was carried out using a Vivaflow 200 CFF module. Exchange 
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against seven volumes involved no changes in the composition of the retentate according to 
a visual inspection. Final concentration to values >20 mg/ml revealed a stability limitation 
resulting in an increase in turbidity. Recovery was 77% after sterile filtration using a 0.2 µm 
membrane. Final 2G12 concentration in the bulk material produced a concentration of 
30.1 mg/ml, resulting in 3.75 g of purified antibody ready for preclinical use. 
Figure III-39 summarizes the purification process including the individual times of each 
process step. Shown is also the total amount of antibody remaining after each purification 
step. 
 
Figure III-39: Process overview including step times and total amount of antibody 2G12. 
Production of antibody included extraction (II.2.3), filtration (II.2.4.1), Protein A capture (II.2.5.3) and HA 
chromatography (II.2.5.4), virus filtration (II.2.6) and ultra- and diafiltration (II.2.7). 
We demonstrated the ability to use large amounts of biomass in this complex process, thus 
the scale-up and large-scale production were successful. 216 kg leaf material resulted in 
880 l crude extract, clarified by three filtration steps to 750 l chromatography loading 
material, containing 6.2 g 2G12. Finally after 2 steps of chromatography, virus filtration and 
final concentration with 0.2 µm filtration 3.75 g of antibody 2G12 could be produced, equal to 
60% total recovery. When considering the complexity and number of process steps, this was 
an excellent result indicating a high level of process control. 
III.13 Characteristics of the final bulk product 
To evaluate the purification process, the intermediates and the final bulk clinical-grade 
material generated by large scale-processing were analyzed extensively by several methods. 
The methods included analytical SEC, residual DNA content analysis, SDS-PAGE, LC/MS, 
nicotine content analysis, glycan characterization and in vitro activity assays. 
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III.13.1 Analytical gel filtration 
Purified SR-12G12 was loaded onto an analytical SEC column and separated according to 
molecular size (II.4.5). The resulting chromatogram (Figure III-40) indicated a highly 
homogeneous antibody population consisting of 99.9% assembled antibody. The elution 
volume of 11.78 ml perfectly fitted the assembled antibody. 
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Figure III-40: Analytical gel filtration of purified SR-12G12. 
Antibody was produced by extraction (II.2.3), filtration (II.2.4.1), capture (II.2.5.3) and intermediate purification 
(II.2.5.4), virus filtration (II.2.6) and ultra- and diafiltration (II.2.7). Sample was parsed by analytical SEC (II.4.5). 
The preparation was homogeneous, comprising 99.9% assembled antibody. The elution volume of 11.78 ml 
perfectly fitted that of the assembled monomeric antibody. 
III.13.2 Protein quantification 
Protein levels were measured using a range of methods to eliminate systematic errors 
reflecting individual measuring principles. The Bradford assay (II.4.8) indicated a 
concentration of 30.3 mg/ml. BSA was used as the reference, using a correction factor of 
0.66 for IgGs as recommended by the manufacturer. Concentration determination by SPR 
(II.4.1) indicated a concentration of 30.1 mg/ml, using CHO-derived 2G12 of known 
concentration as the reference. Gravimetric SR-12G12 concentration measurement indicated a 
concentration of 34.3 mg/ml. 
III.13.3 Residual DNA quantification 
Residual double stranded DNA (dsDNA) was analyzed using the Pico green assay (II.4.7). 
The dsDNA content of the Protein A eluate was found to be <0.9 ng/ml. Quantification was 
not possible because the signal was near the background level, i.e. lower than the detection 
limit of 1 ng/ml. Further removal of DNA was achieved by ceramic HA intermediate 
purification, but more sensitive methods such as threshold or Southern blot hybridization are 
required to measure the residual DNA levels (EDQM 2007). The upper limit for DNA in an 
API is 10 pg/dose, and the recommended concentration of formulated SR-12G12 is 25 mg/ml, 
which means each dose is 1 ml. Thus, the maximum allowable DNA concentration in our 
final product is 10 pg/ml, which is an order of magnitude below the Pico green detection 
threshold. Ideally, the residual DNA should be quantified in an assay with a sensitivity of 
1 pg/ml, which can be achieved by the abovementioned techniques. 
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III.13.4 SDS-PAGE and LC/MS analysis 
Serial dilutions of purified SR-12G12 (III.12) and its CHO-derived counterpart was analyzed by 
SDS-PAGE (II.4.3) under non-reducing conditions for Coomassie staining and under 
reducing conditions for Coomassie staining, silver staining and western blotting (II.4.4). 
Matching band patterns for SR-12G12 and the CHO-derived antibody were observed under 
both electrophoresis conditions as shown in Figure III-41. This indicated that the highly 
purified SR-12G12 lacked degradation products. 
 
Figure III-41: SDS-PAGE of reduced (left) and non-reduced (right) SR-12G12 and CHO2G12. 
Antibody was produced by extraction (II.2.3), filtration (II.2.4.1), capture chromatography (II.2.5.3) and 
intermediate purification (II.2.5.4), virus filtration (II.2.6), ultra- and diafiltration (II.2.7). Antibody sample was 
analyzed by SDS-PAGE (II.4.3). 
The high purity of the antibody was confirmed by silver staining, as shown in Figure III-42. 
The numbered bands in the figure were excised and analyzed further by LC/MS (II.4.10). 
Silver staining confirmed that the antibody was extremely pure and lacked degradation 
products. In bands 1, 3, 5 and 7 only fragments associated with the 2G12 HC could be 
detected (data not shown). In bands 2, 4, 6 and 8 only fragments associated with the 2G12 
LC could be detected (data not shown). 
 
Figure III-42: SDS-PAGE of serial diluted purified SR-12G12 antibody. 
Antibody was produced by extraction (II.2.3), filtration (II.2.4.1), capture chromatography (II.2.5.3) and 
intermediate purification (II.2.5.4), virus filtration (II.2.6), ultra- and diafiltration (II.2.7). Antibody sample was 
analyzed by reducing SDS-PAGE (II.4.3). All the numbered bands were excised for LC/MS analysis (II.4.10). 
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Western blots also confirmed the match between CHO- and tobacco-derived antibodies as 
shown in Figure III-43. All bands detected in the SR-1 samples were also found in the CHO-
samples, and it was possible to detect minute amounts of degradation products (bands 
between the HC and LC) as well as some larger product-related impurities in the CHO-
reference. 
 
Figure III-43: Western blot of CHO- and tobacco-derived antibody after serial dilution. 
Antibody was produced by extraction (II.2.3), filtration (II.2.4.1), capture chromatography (II.2.5.3) and 
intermediate purification (II.2.5.4), virus filtration (II.2.6), ultra- and diafiltration (II.2.7). Antibody sample was 
analyzed by reducing SDS-PAGE (II.4.3) and western blot (II.4.4). 
In summary the purified tobacco-derived antibody 2G12 was very pure, without significant 
degradation products. All bands observed on reducing and non-reducing gels were 
reproduced when treating the CHO-derived antibody, indicating the two products were very 
similar. 
III.13.5 Nicotine content 
The Protein A eluate was analyzed for the presence of nicotine according to II.4.6. Nicotine 
was not detectable in a 1000 ml sample volume with the method we used, whose detection 
limit was 5 ppm. Given the 333-fold concentration during sample preparation and the 
recovery of 83% of the nicotine in a spiked sample, these data suggest that nicotine 
concentration after the Protein A capture step is lower than 18 ppb. The experiment layout 
cannot be used routinely in process monitoring because large volumes of the valuable 
Protein A eluate are consumed. 
III.13.6 N-glycan profile 
The HA eluate monomeric antibody fraction was analyzed to determine the structure and 
distribution of N-glycans as described in II.4.11. Only one type of plant-specific glycan, 
consisting of β(1,2)-xylose and α(1,3)-fucose linked to the proximal N-acetylglucosamine, 
was found, indicating that the 2G12 produced in tobacco had a largely homogeneous glycan 
profile as shown in Figure III-44. 
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Figure III-44: N-glycan profile of purified SR-12G12. 
Antibody, purified by extraction (II.2.3), filtration (II.2.4.1), capture chromatography (II.2.5.3) and intermediate 
purification (II.2.5.4), was analyzed regarding the glycosylation profile (II.4.11). The two peaks represent 
overlapping peptides. 
Two major peaks were identified but these were overlapping peptides representing the same 
glycosylated asparagine residue (N-298). 
III.13.7 In vitro binding of gp120  
The ability of the tobacco-derived 2G12 antibody to bind its antigen, HIV gp120, was tested 
by SPR (II.4.1) in an in vitro assay. The average relative activity of the antibody compared to 
its CHO counterpart was 87 ± 4.4% (Figure III-45). 
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Figure III-45: Activity of SR-12G12 relative to that of CHO2G12. 
20 Protein A eluates, produced during the processing of 240 kg of tobacco leaves by extraction (II.2.3), filtration 
(II.2.4.1) and capture chromatography (II.2.5.3), were analyzed regarding the in vitro binding activity by SPR 
(II.4.1). 
The SPR measurements have a standard error of approximately 10%, so our observed 
standard deviation of 4.4% over 20 measurements fell within the measuring range. This 
indicated there were no significant differences between individual Protein A eluates, 
confirming the process intermediate was homogeneous after Protein A capture. 
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The clinical-grade bulk material produced under GMP conditions for preclinical testing (as 
described in III.12) had an activity of 93% relative to the CHO2G12, once again highlighting the 
process reliability and the predictable characteristics of the final product. 
III.13.8 Neutralizing activity 
A virus neutralization assay was carried out as described in II.4.12. The results for the plant-
derived antibody compared to its CHO-derived counterpart are shown in Table III-6. The 
neutralizing activity of the SR-12G12 assembled antibody fraction was comparable to the 
CHO2G12 control, with IC50 values of 7.20 µg/ml and 7.40 µg/ml, respectively. The three-fold 
higher neutralizing efficiency of the SR-12G12 fraction containing 55% dimers was anticipated, 
although up to 10-fold higher efficiency would have been unremarkable (Castilla et al. 1997; 
Renegar et al. 1998; Wolbank et al. 2003). 
Table III-6: IC50 values for the tobacco-derived 2G12 antibody and its CHO derived equivalent. 
The monomeric and dimeric antibody fractions, produced by extraction (II.2.3), filtration (II.2.4.1), capture 
chromatography (II.2.5.3) and intermediate purification (II.2.5.4), were analyzed regarding the in vitro 
neutralization efficiency (II.4.12). 
Sample IC50 [µg/ml] Relative efficiency [%] 
CHO2G12 7.40 100 
SR-12G12 (99.9 Monomers) 7.20 103 
SR-12G12 (45 % monomers, 55 % dimers) 2.23 332 
The overall process, consisting of dispersion, particle removal, clarification, Protein A capture 
and ceramic HA purification, virus removal for polishing and final ultra- and diafiltration 
proved to be an excellent arrangement of unit operations for the purification of an active, 
homogeneous and very pure plant-made antibody, 2G12. 
III.14 Design of the large-scale processing system 
We have already described the processing of up to 240 kg of leafy tobacco material with in-
house equipment in III.12. For GMP-compliant production of large amounts of antibody in 
short time (e.g. one working day) a large-scale processing system was designed and User 
Requirement Specifications (URS) generated as a guideline for engineering. The process is 
outlined as shown below. 
Surface cleaning shall be carried out by treatment with water or a dilute bleach solution, as 
appropriate for the starting material. When using bleach solution, a rinsing step with water 
shall be applied after the treatment. Disintegration of leaf material and wet-milling of seeds, 
respectively, shall be performed using a suitable combination of pre-dispersion and fine-
dispersion steps in a closed vessel capable of maintaining a constant temperature by cooling 
during operation and allowing treatment with an inert gas (N2) during operation. The resulting 
aqueous extract shall be transferred inline to the initial filtration component of the device 
without intermediate external storage. Filtration operations shall be applied to the aqueous 
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extract immediately after dispersion/milling. A suitable combination of sequential depth and 
membrane filtration steps shall be applied to the extracts to remove fibrous plant material, 
cell clusters and cell debris as well as fine particles. The device shall be designed to allow 
continuous process flow with minimal holding times. Capacities of the disintegration and 
filtration components shall be appropriately matched to minimize the volumes of intermediate 
storage tanks, which are also part of the device. Exchange of device components that have 
reached their capacity (e.g. filter capsules) shall be possible without interrupting the process. 
The end-product of the operations shall be collected in a mobile, temperature-controlled tank 
which is also part of the device. The complete sequence of operations from disintegration to 
final (0.2 µm) filtration shall be performed in a closed system to minimize contact between 
the intermediates and oxygen, and to minimize the introduction of exogenous 
contaminations. 
Upscaling the flow rate during filtration and capture chromatography enables the processing 
of 200–250 kg tobacco leaves in one working day. This amount of biomass is the current 
capacity of in-house production in the IME greenhouses, and results in 1000 l of crude 
extract. Approximately 800 l will be retained after fiber removal and clarification for capture 
chromatography. An increase from 200 ml/min to 3000 ml/min for clarification and from 
333 ml/min to 3000 ml/min for capture chromatography facilitates the processing of the 
estimated volume in less than five hours. For time saving purposes, all steps of the process 
will be carried out simultaneously, once enough liquid is available to start the next process 
step. 
Several changes have to be considered during scale-up for optimal large-scale process 
performance: 
• Leaf material must be cleaned after harvest 
• Tobacco leaf disintegration needs two dispersion units to guarantee continuous 
filtration 
• 25 kg leaf mass per dispersion run 
• Increase of filtration and chromatography flow rate to 3000 ml/min 
• pH-adjustment step is moved from dispersion unit to the intermediate buffer tank after 
fiber removal ? continuous pH-adjustment during whole process 
• All filtration steps are constructed in a redundant manner to guarantee continuous 
flow during filtration 
• Depth filtration steps consist of multilayer depth filter modules 
• Depth filter modules will be disposable multilayer stack modules, 12” in diameter, 
2 m² per module. Up to four modules can be driven in parallel 
• The capture chromatography step by Protein A should be redundant to achieve 
continuous capture from the clarified extract. 
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The large-scale processing device will be modular to provide flexibility for optimal storage 
when the system is not in use. Additionally, single system components can be used without 
setting up the complete system. Thus each component of the system will get its own skid. In 
total ten skids will accommodate all necessary system components: 
• Skids 1+2:  each one washing machine for surface cleaning 
• Skids 3+4:  each one dispersion unit with drives and cooled vessel 
• Skid 5: duplicate bag filter housings with pump and cooled filtrate bag with 
agitator for pH-adjustment 
• Skid 6:  duplicate filter strains for 1.2 µm Sartopore PP2 (up to 8 capsules in 
parallel) or alternatively C3P/F4HP multilayer modules (up to four 
modules in parallel) with pump and cooled filtrate bag 
• Skid 7:  duplicate strains for C4P/F7HP multilayer modules (up to 4 modules in 
parallel) with pump and cooled filtrate bag  
• Skid 8:  duplicate strains for F7HP/S5P/membrane multilayer modules (up to 4 
modules in parallel) with pump and cooled filtrate bag 
• Skid 9:  duplicate strains for 0.45/0.2 µm membrane filter (up to 4 capsules in 
parallel) with pump and cooled filtrate bag 
• Skid 10:  duplicate MA modules with feed pump 
If necessary, the skids will be equipped with suitable instruments to monitor, and if required 
to control, the following parameters: mass, pH, conductivity, turbidity, pressure, flow, pump 
speed and rotation speed of the cutting device. Figure III-46 shows the technical draft of the 
process system with all measuring elements. 
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Figure III-46: Technical drawing of the large scale processing device. 
The System will consist of ten independent skids, each for one process step. The skids will be connected by 
flexible tubing as well as data cables. (Drawing by Jens Braun, Sartorius Stedim Biotech) (This represented the 
latest version before thesis completion, but subject to revision.) 
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Processing of 200 kg leaf material should be accomplished in one working day. Figure III-47 
shows the theoretical time table for this downstream process. 
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0 30 60 90 120 150 180 210 240 270 300 330 360 390
MA capture
Clarification PCI 1/0.3/0.1
Clarification PBII 8/1
Fiber removal
Vessel emptying
Dispersion
Washing
Harvest
Pr
oc
es
s 
st
ep
Time [min]  
Figure III-47: Theoretical time table of the large-scale processing device. 
Processing of 200 kg tobacco leaf material is possible within 6 h, including extraction (II.2.3), filtration (II.2.4.1) 
and capture chromatography (II.2.5.3) 
All process steps from harvest to MA capture are included and finished in less than 6 h. 
Harvest, washing and dispersion are performed in sub-batch mode, while filtration will run in 
continuous mode. Capture by membrane chromatography will generate three eluates, which 
will be combined before further processing by HA chromatography. 
III.14.1 Washing of tobacco leaves 
The washing of tobacco leaves is achieved by techniques known from the food industry. A 
SWA 100 (AlexanderSolia, Remscheid, Germany) was evaluated in terms of cleaning 
performance and efficiency. The cleaning performance was inspected visually and found to 
be adequate, since both dust and sticky leaf surface components could be removed. The 
throughput was 60 kg/h at 4 kg per run. This rate is adequate to provide the dispersion units 
downstream with clean leaf material in 25 kg batches. 
III.14.2 Dispersion of tobacco leaf material 
Dispersion of plant material will be performed in two devices, running in alternate cycles. 
While one device is fed with 25 kg of cleaned tobacco leaves and 75 kg of buffer, and then 
initiates the dispersal process, the other is connected to the filtration train. When the second 
vessel is empty, the filtration connection switches to the first vessel where dispersal is now 
complete, allowing continuous filtration. The temperature and rotation speed of the cutting 
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knives will be monitored and controlled. 25 kg of leaves will be inserted after washing. The 
dispersion time is <10 min per cycle. 
III.14.3 Fiber removal by bag filter and pH adjustment 
The first filtration step is constructed with duplicate modules mounted onto one skid. Scale-
up is achieved by inserting four bags into one housing to attain the necessary flow rate of 
3750 ml/min. The single bag size is equal to the pilot scale set up. Four bags per housing 
anticipate the collection of 60 kg of filter cake, resulting in a housing life time of 106 min, 
equal to 400 l crude extract. 
The pH will be adjusted continuously in the bag filtrate. An extract flow of 3000 ml/min 
requires buffer H to be fed into the closed bag at ~80 ml/min. Permanent stirring ensures 
mixing of the buffer with the filtrate. 
III.14.4 Clarification of the plant extract 
Clarification will be achieved using depth filtration materials from Sartorius Stedim Biotech. 
Instead of the single-layer depth filter used for process development, the final process will 
employ multilayer stack filters, which will be completely disposable thus circumventing the 
need to clean the stainless steel housing or hard-piped equipment. Additionally the multilayer 
filters last longer than single-layer modules. Instead of F7HP (1 µm) and S5P (0.3 µm) filters 
for clarification, the final process will employ the filter types “Post Bioreactor 2” (PB2) and 
“Post Centrifuge 1” (PC1). PB2 consists of C4P (8 µm) and F7HP (1 µm) and PC1 consists 
of F7HP, S5P and an additional 0.1 µm filter membrane. The abovementioned retention rates 
are nominal, and thus do not represent an exact cutoff. Laboratory scale experiments 
indicated a filter lifetime of 103 l/m² for PB2 and >200 l/m² for PC1 in the abovementioned 
filtration series. For comparison, the single layer 1 µm filter had a lifetime of 61 l/m². The full 
disposable modules are 12” in diameter and offer a filter area of 2 m². Each filter step will be 
used at a flow rate of 3 l/min. Filters will be exchanged at a pressure drop of 2 bars or at 
turbidities greater than 200 NTU for PB2 and 10 NTU for PC1. 
III.14.5 Final 0.2 µm filtration and capture by membrane adsorbers 
Although 0.1 µm filtration was part of the clarification operation, a Sartopore2 0.45/0.2 µm 
filter will be used immediately before capturing to ultimately protect the MA from adventitious 
particles. Capture chromatography will be carried out using an ÄKTAprocess skid (GE 
Healthcare, Munich) with two redundant MAs, each with a membrane volume of 840 ml. The 
capacity will be 210 l clarified extract per module, equivalent to 1.7 g of antibody. After 
loading the first MA with antibody, the wash, elution, CIP and equilibration steps will be 
carried out in sequence while the second MA is loaded, to achieve a quasi-continuous mode 
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of chromatography. Rough estimates indicate that three MA runs will be required per 200 kg 
batch. The resulting elution volume will be approximately 7600 ml (= three runs at 3x MV). 
III.14.6 Intermediate purification by hydroxyapatite 
The combined Protein A eluates will be polished by ceramic HA chromatography. The up-
scaled column volume will be 1100 ml at an average antibody load of 4 mg/ml. A column 
diameter of 10 cm will achieve a suitable column layout, controlled by an ÄKTApilot system 
(GE Healthcare, Munich). A flow rate of 150 cm/h will result in a contact time of 5.5 min. 
Column packing at the process scale differs from laboratory-scale packing procedures. 
Agitation of the resin slurry by nitrogen is recommended to achieve a high quality column 
with an asymmetry factor close to 1 and low HETP values. 
III.14.7 Virus filtration 
After intermediate purification by ceramic HA chromatography, a virus filtration step will be 
carried out as described in II.2.6, using a ÄKTApilot controller and a Virosart CPV capsule at 
an operational pressure of 2.5 bars. 
III.14.8 Ultrafiltration and diafiltration 
Concentration and diafiltration for buffer exchange will be carried out using a Sartoflow Alpha 
cross flow skid as described in II.2.7. If the desired volume is smaller than the dead volume 
of this skid, an additional concentration will be carried out by utilizing a disposable single use 
Vivaflow 200 CFF module. Concentration volumes as low as 30 ml should be achievable. 
III.15 Extra-professional results 
The capture of 2G12 generated large volumes of extract in the Protein A flow-through (see 
III.12). This extract was red-colored indicating high concentrations of the DsRed marker 
protein, and since the extract was already clarified it offered a useful by-product that could be 
used for DsRed purification, which was carried out according to II.2.8. A flow diagram 
outlines the process in Figure III-48. 
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Figure III-48: Flow diagram for complete DsRed purification. 
The flow path was identical to the 2G12 purification train until the Protein A step (extraction (II.2.3), filtration 
(II.2.4.1), antibody capture (II.2.5.3)). Here, the flow-through was heated to 65°C, followed by gravity 
sedimentation of precipitate and 0.3 µm depth filtration. Isolation of DsRed from the extract was achieved using a 
Cu-IMAC column controlled by BioProcess skid (II.2.8). The eluate was concentrated further and dialyzed before 
final 0.2 µm filtration. 
SDS-PAGE analysis of the Protein A flow-through fraction revealed high levels of plant 
proteins, mainly Rubisco, which bound to a Cu-IMAC column (data not shown). To remove 
the contaminating plant proteins the extract was heated to 65°C (see Figure III-49), using an 
Applicon bioreactor with 30 l working volume. The extract was pumped upward through the 
reactor (capacity 35 l) at 2.75 l/min resulting in a mean contact time of 12.7 min. 
 
Figure III-49: Coomassie stained SDS-gel of the protein heat precipitation study. 
The Protein A flow-through, generated by extraction (II.2.3), filtration (II.2.4.1) and antibody capture (II.2.5.3), was 
heated to 65°C (II.2.8). Samples were analyzed by SDS-PAGE (II.4.3). Protein bands >120 kDa represented non-
reduced DsRed. 
Non-reduced DsRed 
Rubisco large subunit 
DsRed 
Rubisco small subunit 
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The heat-treated extract was cooled to <10°C and stored overnight to sediment the 
precipitated proteins. The next day, 680 l of clear supernatant was passed through a 0.3 µm 
Sartoclear 12” filter module (refer to III.6.2), with a filter lifetime of >380 l/m². The turbidity of 
the filtrate was <5 NTU. To reduce nonspecific ionic interactions between extract 
components and the chromatographic resin, the salt concentration was increased by 0.2 M 
by adding NaCl in solid form to reach a final salt concentration of approximately 0.6 M in the 
extract. The turbidity did not increase during this procedure. A 3.85 l chelating Sepharose 
column was prepared by immobilizing Cu2+ ions onto the matrix. The extract was loaded onto 
the column, which was equilibrated in buffer M. A 0.2 µm inline filter guaranteed that the 
column feed stream was particle free. The linear flow rate was only 60 cm/h because of back 
pressure limitations, in contrast to the 300 cm/h achieved in laboratory-scale experiments. 
Interestingly, at this low flow rate, the capacity increased by factor of seven. The capacity 
increase could be reproduced at the laboratory-scale when using a linear flow rate of 
60 cm/h. The total volume of 680 l could be loaded onto the column resulting in a capacity of 
176 CV. 
Since DsRed is a visually recognizable protein, column capacity could be determined by eye, 
no break through of DsRed could be observed. During loading, immobilized copper was 
leached from the column inlet, resulting in a lower portion of column matrix used for DsRed 
binding. Approximately 40% of the column consisted of leached matrix after applying 680 l of 
the plant extract. The remaining 60% non-leached column volume achieved a capacity of 
43 mg/ml, calculated from the amount of eluted protein. The leaching was caused by other 
plant proteins or metabolites which were not investigated further. When applying pure 
extraction buffer, no Cu-leaching was observed. After washing with buffer M, elution was 
initiated with buffer N (see Figure III-50). The eluate was passed through a 0.2 µm filter 
before collection in a bag. 
                
Figure III-50: Cu-IMAC during washing (left) and elution of DsRed (right). 
Clarified tobacco extract, generated by extraction (II.2.3), filtration (II.2.4.1), antibody capture (II.2.5.3) and heat 
treatment (II.2.8), was loaded onto the Cu-IMAC column (II.2.8). (left) The bright upper part of the column (40% 
CV) corresponded to Cu-leached matrix, whereas the dark red lower part showed bound DsRed. (right) The 
BioProcess controller piping showed a strong red color during elution. 
The column had a very sharp elution profile, resulting in an elution volume of only 5.11 l, 
equal to 1.3 CV. The progress of the purification is shown in Figure III-51. 
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Figure III-51: SDS-PAGE of DsRed purification. 
Extract, generated during antibody purification by extraction (II.2.3), filtration (II.2.4.1) and antibody capture 
(II.2.5.3), was heated to 65°C, followed by filtration and Cu-IMAC (II.2.8). Extract and IMAC-eluate samples were 
analyzed by SDS-PAGE (II.4.3). (2 – Protein A flow-through; 3 – after heat treatment; 4 – Cu-IMAC flow-through; 
5 – Cu-IMAC elution) 
SDS-PAGE indicated the DsRed was 95% pure and lacked degradation products as shown 
in Figure III-52. Analytical SEC (II.4.5) showed that 89% of the DsRed comprised the natural 
tetramer, 11% comprised higher aggregates and there was no significant amount of the 
monomeric protein. The protein concentration was 18.0 mg/ml when determined by UV280 
measurement (II.4.8), and 19.8 mg/ml when using the Bradford assay. In combination with 
the elution volume, these measurements indicated that 92–102 g of recombinant DsRed was 
purified by this method. The eluate was concentrated to 110 mg/ml in a volume of 800 ml 
using a cross-flow filtration Sartoflow Alpha skid with a Hydrosart 10 kDa. Dialysis followed 
against seven volumes of 25 mM NaH2PO4 pH 7.5. A decrease in concentration to 
100 mg/ml and thus a loss of DsRed during final sterile filtration indicated the stability limit of 
DsRed had been reached. Finally 800 ml of 100 mg/ml concentrate was purified, resulting in 
80 g of pure recombinant DsRed. 
 
Figure III-52: Purified DsRed after Cu-IMAC. 
DsRed, purified by extraction (II.2.3), filtration (II.2.4.1) and heat precipitation in combination with sedimentation, 
Cu-IMAC and DF/UF (II.2.8), was analyzed by SDS-PAGE (II.4.3) in a serial dilution. 
The yield of DsRed reflected the enormous recombinant protein production capability of the 
tobacco plant expression system, equivalent to at least 430 mgDsRed/kgtobacco. Unfortunately 
this high potential could not be achieved with the primary target, 2G12, but it hints at what 
could be achieved with tobacco under ideal conditions. 
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IV Final discussion and perspectives 
The aim of this thesis within the EU founded project Pharma-Planta was to develop and 
optimize downstream processing strategies for the purification of the recombinant anti-HIV 
antibody 2G12. Different techniques were successfully combined into a process strategy to 
fulfill these aims. Recombinant clinical-grade antibody was purified by following the steps 
listed below using industrially available equipment: 
• Manual harvest 
• Dispersion and extraction 
• pH shift in the crude extract 
• Fiber removal by filtration 
• Clarification by filtration 
• Capture by affinity Protein A membrane chromatography 
• Intermediate purification by ceramic hydroxyapatite chromatography 
• Polishing by virus filtration 
• Concentration by ultrafiltration 
• Diafiltration by ultrafiltration 
• Final concentration and formulation 
This thesis has established the basis for reproducible and predictable processing of plant 
material at the hundred-kilogram scale, but even larger scales can be envisaged. 
Furthermore, the final product was clinical-grade quality, ready for use in preclinical testing.  
IV.1 Current purification process 
Extraction experiments showed optimal conditions for phosphate buffer at pH 7.5 with the 
addition of NaCl as indicated in the literature (Evangelista et al. 1998; Bai and Nikolov 2001; 
Balasubramaniam et al. 2003). 
Dispersion of tobacco leaves was optimized at the pilot scale. Commercially available 
systems showed significant disadvantages (III.4), which were overcome by redesigning the 
cutting tools. New Polytron tools with self-cleaning characteristics were introduced (III.4.1) 
and the second, fine dispersion unit Megatron was no longer necessary for this type of plant 
material and protein targeting. For different combinations of plant material and targeting 
(Hassan et al. 2008) the new Megatron generator (III.4.1) will be advantageous providing 
higher shear forces than the Polytron. 
Fiber removal at the laboratory and pilot scales was achieved using specially developed 
filter capsules, which are disposable to avoid cleaning and validation (III.5.1). The gap 
between pilot and production scales was closed by using bag filters for pharmaceutical 
processing (III.5.2). Only these filter devices were able to manage the huge amounts of 
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separated filter cake at high flow rates. In this case, intensive cleaning was needed because 
of the steel housing. Nevertheless, their use avoided the enormous investment required for 
continuous centrifuges as suggested by Lico et al (2008). 
Clarification was accomplished by consecutive depth filtration. Scalable filtration modules 
from 25 cm² to 1.8 m² were used from process development to production scale. A 1 µm 
Sartoclear depth filter was used as the main clarification step, followed by a 0.3 µm 
Sartoclear depth filter for polishing and safeguarding. A final 0.2 µm filter was integrated 
inline to the capture device to protect the downstream chromatography media from fouling 
(Menkhaus and Glatz 2004; Holler et al. 2007). The clarification method based on HFF 
(III.6.1) performed poorly (low transfer of antibody across the membrane as well as 
significant membrane cleaning problems). Problematic membrane fouling has also been 
reported for tangential microfiltration (Mercille et al. 1994). The antibody recovery of 59% 
was significantly lower than values found in the literature for CCF filtration (Maiorella et al. 
1991). There are no comparable values for plant extract CFF in the literature. A further 
optimized process strategy with back flushing the membrane, varying the pore size and 
membrane material might be advantageous to increase the antibody passage. 
Capture of the antibody was achieved using membrane chromatography with a Protein A 
ligand. A 156 ml module captured the antibody from 50 l of clarified extract within 2 h. The 
capture process was reliable, and the eluates had reproducible characteristics (III.7.2.3). 
There was no yellowing of the capture eluate due to the presence of secondary metabolites 
as previously reported (Valdes et al. 2003). The average recovery of 80% was comparable to 
previous reports by Giovannini and Freitag (2001) (77-82%) and Gonzalez et al. (2003) 
(92%). Nicotine could not be detected (<18 ppb) in the affinity chromatography eluate. 
Intermediate purification was carried out by ceramic hydroxyapatite chromatography 
(III.8.2), as described in numerous protocols (Stanker et al. 1985; Bukovsky and Kennett 
1987; Poiesi et al. 1989). The relative abundance of assembled single antibody molecules 
was increased by delaying the elution of aggregates. Furthermore hydroxyapatite is known to 
reduce HCP, DNA and endotoxins (Kawasaki 1991; Guerrier et al. 2001; Ng 2005). The 
accomplished recovery rate of 95% is similar to the 87-92% reported by Giovannini and 
Freitag (2001). Further antibody separation optimization might be possible by adding 
polyethylene glycol as described by Ganon (2008). 
Polishing by virus reduction was achieved by virus filtration (III.9), which retained viral 
particles >20 nm. A step recovery of 95% enabled the integration of this unit operation into 
the purification process. 
Dialysis and concentration was accomplished by ultrafiltration and diafiltration using cross-
flow filtration skids (III.10). The operations showed a step recovery of 99%, but revealed an 
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upper concentration limit for SR-12G12. A final concentration of 30.1 mg/ml in saline was 
achieved. CFF proved to be an integral unit operation within this process. 
Scale-up and production of large amounts of clinical-grade material for preclinical 
testing (up 240 kg plant material per batch) exceeded the initial aims of this thesis (III.12). 
The purification of 3.7 g SR-12G12 from 216 kg tobacco leaf material at a total process 
recovery of 60% was achieved by processing 880 l crude extract. After the removal of 130 kg 
of filter cake during clarification, 750 l clarified extract was processed by Protein A membrane 
chromatography, resulting in 4.4 l of eluate. The amount of finally purified antibody exceeds 
comparable purifications, e.g. Valdés et al. (2003) who purified 1.8 g antibody (47% total 
recovery) from 208 kg leaf material using centrifuges and Protein A expanded bed 
adsorption, yet producing an antibody still contaminated with product- and process-related 
impurities. 
Designing a large-scale processing device was initiated during this project (III.14), 
surpassing the initial objectives of this dissertation. Redundant equipment will facilitate 
continuous processing of plant biomass. Filters reaching their lifetime can be exchanged 
without stopping the whole process. Additionally, working with small single filter lifetimes 
enables the flexible processing of smaller batches for research purposes. The fundamental 
design was achieved, planning of detailed control setup and automation is still in progress. 
Storage conditions for virus inactivation and intermediate holding steps were investigated 
(III.11). Virus inactivation conditions were acceptable for 4 h; no significant changes in 
Protein A eluate composition were observed. Long-term storage at -80°C is recommended, 
but storage at 4°C is adequate for short periods (<3 days). 
The purification of 80 g of recombinant DsRed was achieved as an additional result 
exceeding the initial goals of the thesis. The 100 g of purified recombinant DsRed produced 
after chromatography reflected the enormous production capacity of the tobacco plant 
expression system under ideal circumstances. This also reflects the versatility of the in-
house DSP suite, which was adapted to process two >700 l feed streams for two different 
and complex downstream strategies for the isolation of two distinct proteins with different 
properties to a purity of >99% (2G12) and >95% (DsRed). 
IV.2 Considerations for agricultural scale-up 
Scaling the process described herein to agricultural dimensions with an input of several tons 
of plant material would affect all the individual process steps. The techniques underlying 
these steps would likely remain unchanged, and the further downstream the less change 
would be necessary. However, growing plants in a field means that the environment is 
undefined and variable, and thus the process is subject to less control than greenhouse 
cultivation. The soil type, irrigation frequency, sunlight intensity and temperature fluctuations 
will all influence plant growth and differ from greenhouse conditions (Ichimura et al. 2000). 
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The monitoring of individual plants for health indicators, including pest control, would no 
longer be feasible and a more general approach would be required, such as regular 
inspection of representative plant populations. Damage caused by larger animals should be 
avoided even on an agricultural scale. 
One important consideration is the use of agricultural machinery for harvesting. Although 
such machines are commercially available, contamination of the plant biomass with animal 
material should be prevented which is a challenging demand. Separation of leafs from stems 
might not be practical on a large scale so the plants might need to be processed completely. 
Only a few proteins show mid-term stability at RT (Fiedler et al. 1997) and to hinder tobacco 
from stress reactions caused by wounding (Bowles 1993; Ichimura et al. 2000) immediate 
processing would be crucial. Cooling might be advantageous while the biomass is 
transported from the field to the purification facility. Alternatively, immediately freezing of the 
biomass would protect the target molecule from damage (Fischer et al. 2003). Cleaning of 
the surfaces of leaves and seeds will become a critical stage of the process, to avoid 
contamination with exogenous agents such as fungi and their metabolites (Fischer et al. 
1999). When processing leafy green biomass, surface cleaning must remove the dust, dirt 
(soil) and sticky components. The next process steps must take place in a contained system 
within a non-clean room environment. Components used for continuous liquid processing 
must be redundant, especially if their capacity does not match the required lifetime. As 
described in III.14, the planning for such a facility is in progress for processing up to 250 kg 
of tobacco leaf material per batch in one working day. All techniques utilized in this facility 
can be scaled up directly to cope with agricultural production. The dispersion unit is the first 
part of the closed system, and should therefore include self-cleaning cutting tools to limit 
exposure times. The preservation of sharp cutting edges is critical for dispersion of material 
containing high fiber content. Successful clarification depends on pretreatment so that the 
extract is compatible for handling with commercially available filter devices commonly used in 
CCF processing. Ordinary depth filtration requires this pretreatment because of the solids 
load, as mentioned in III.5.2 and by Menkhaus et al. (2004). At very large scales, higher 
investment costs might be acceptable. Decanters or separators, used in the food, beverage 
and mineral oil industries (Westfalia 2008), may be useful alternatives for fiber removal and 
initial clarification of the extract at agricultural scales, although they require immense 
investment costs. Additionally they operate in continuous mode, so there would be no need 
for redundant installation. Valdés et al. (2003) successfully used continuous centrifuges to 
remove particles from tobacco extracts, but these complex devices are not disposable, 
leading to higher cleaning and validation costs. Final clarification can be achieved using 
common disposable depth filtration cartridges incorporating filters with several square meters 
of filter area. 
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Antibody capture will be accomplished by chromatography, most likely Protein A affinity 
chromatography. The decision to use packed-bed columns or membranes would reflect the 
cost-benefit of each device and their performance under load, which would depend on the 
antibody expression levels. This should be evaluated on a case by case basis. Intermediate 
purification and polishing of the antibody will be achieved by conventional packed bed or 
membrane chromatography in combination with virus filtration, ultra- and diafiltration. 
IV.3 Economic aspects 
The process developed in this project aimed to go one step beyond the established principle 
of expressing recombinant proteins in plants. The scale of production influences the 
economic feasibility of the process. Upstream production costs will not increase linearly with 
the cultivated field area, since agricultural techniques allow the cultivation of pharmaceutical 
plants at minimal cost especially on very large scales (Fischer et al. 2003; Stoger et al. 
2005). The expression level of recombinant proteins can determine whether a process is 
economical or not. The process described herein is not economically competitive with 
antibodies produced in mammalian cells because of the comparative low yields. Several 
challenges remain to increase expression levels, and increasing the antibody concentration 
100 or 1000 times in the crude extract would make the process competitive with CCF 
processing (Ma et al. 2003; Havenga et al. 2008). Different antibodies produced in-house 
already exceed the yields of 2G12 ten-fold (Raven 2007, personal communication, data not 
shown). The process from cultivation to final clarification would remain the same, increasing 
the economy of the process 100–1000 fold. The routine production of antibodies on a large 
scale would justify initial high investments for decanters and similar major equipment costs, 
but this reduces the likelihood that such devices would be replaced by disposables. Common 
clarification devices such as depth filters are available in disposable formats in sizes up to 
several square meters, and using such devices in parallel increases the scale even further. 
Higher expression levels would demand some changes in the chromatography resins, e.g. 
the initial investment costs would increase due to larger bed volumes. 
IV.4 Activities necessary to achieve GMP compliance  
Converting the process described herein into a GMP-compliant process would require a 
number of changes, including increasing the sensitivity of analytical methods to detect 
residual DNA, HCP, endotoxins and secondary metabolites. HCP for example will be 
analyzed by western blotting using a polyclonal serum against tobacco proteins. A mock run 
(FDA 1993) Protein A capture of wild type tobacco extract generates material containing 
nonspecific binding substances for immunization of animals. This procedure is undergoing 
development. Furthermore standard operating procedures (SOP) must be developed for 
every process step. Process characterization (Seely and Seely 2003) must be carried out to 
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fulfill the regulatory filing package. However, preclinical manufacturing processes are often 
not characterized in detail (Shukla et al. 2007). Operational and performance parameters are 
characterized as non-key, key or critical. Alert and action limits as well as process 
acceptance criteria must be implemented for process validation (Shukla et al. 2007). Process 
validation is defined as “... providing documented evidence that the process, operated within 
established parameters, can perform effectively and reproducibly to produce an intermediate 
or API meeting its predetermined specifications and quality attributes” (FDA 2001). Figure 
IV-1 shows the complexity and enormous labor needed for processes validation. Roughly 
12–15 months are already needed for process characterization (Seely and Seely 2003). 
 
Figure IV-1: Flow chart from decision to commercialize through to product launch. 
A draft of the complex process characterization including screening experiments is shown. (Terms and structure 
from Kaltenbrunner et al. (2007)) 
The terms “master cell bank” (MCB) and “working cell bank” (WCB) must eventually be 
adapted to the plant expression system. The MCB will be converted into the “master seed 
bank” (MSB), providing the seeds for the consecutive plant generations building up the 
“working seed bank” (WSB). Seeds in the WSB will be cultivated to produce the biomass 
used in the production process. Currently, SOPs, parameters and acceptance criteria for 
process validation are in the process of being established and developed. 
 
 
Process 
Characterization
 
Process 
Validation 
 
Regulatory 
Submission 
 
Decision to 
Commercialize 
 
Approval & 
Product 
Launch 
 
Screening 
Experiments 
Interaction & 
Response 
Surface 
Studies 
 
Worst Case 
Studies 
 
Definition of 
Validation 
Limits 
 
 
Risk Analyses 
 
Execution of 
Experiments 
 
Analytical 
Testing 
 
Elimination 
of non-key 
parameters 
Fractional 
Factorial 
Experimental 
Design 
 
Process 
Optimization 
SUMMARY 
 82 
V Summary 
The production of recombinant therapeutic proteins is becoming increasingly important as 
demand rises and the industry reaches its production capacity. Transgenic plants offer an 
alternative production system to the established platforms, but this requires the development 
of downstream processing schemes tailored for both the platform and the product. The aim 
of this thesis, within the EU-funded project Pharma-Planta, was to develop and optimize 
downstream processing strategies for the purification of the recombinant anti-HIV antibody 
2G12. Different techniques were successfully combined into a process strategy to fulfill this 
objective. Clinical-grade recombinant antibody was purified using by the following process 
steps and industrially available equipment: 
• Manual harvest 
• Dispersion and extraction 
• pH shift in the crude extract 
• Fiber removal by filtration 
• Clarification by filtration 
• Capture by affinity Protein A membrane chromatography 
• Intermediate purification by ceramic hydroxyapatite chromatography 
• Polishing by virus filtration 
• Concentration by ultrafiltration 
• Diafiltration by ultrafiltration 
• Final concentration and formulation 
The process recovery of 60% resulted in a final yield of 3.7 g of clinical-grade tobacco-
derived antibody purified from 216 kg leaf material, equal to 880 l crude extract. The antibody 
was polished to a purity >99%, consisting of 99.9% monomeric Ab with an in vitro binding 
activity of 93% and an in vitro neutralizing activity of 103% relative to the CHO2G12. 
This thesis established the basis for reproducible and predictable processing of plant 
material at the hundred-kilogram scale, and shows how further upscaling could be achieved. 
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VII Appendix 
VII.1 Index of abbreviations 
°C   degrees Celsius 
CHO2G12  antibody 2G12 produced in CHO-cells 
SR-12G12  antibody 2G12 produced in Nicotiana tabacum cv. SR-1 
A   ampere 
Ab   antibody 
AC   affinity chromatography 
AEC   anion exchange chromatography 
AIDS   acquired immune deficiency syndrome 
AP   alkaline phosphatase 
API   active pharmaceutical ingredient 
BA   buffer A (plant extraction, MA equilibration and wash) 
BB   buffer B (MA wash) 
BC   buffer C (MA elution) 
BCIP   5-Bromo-4-chloro-3-indolyl phosphate, toluidine salt 
BD   buffer D (MA CIP) 
BE   buffer E (MA storage) 
BF   solution F (BioProcess CIP, HA Storage, CU-IMAC CIP)) 
BG   solution G (BioProcess storage, Cu-IMAC storage) 
BH   buffer H (pH-shift in crude extract, HA CIP) 
BJ   buffer J (HA equilibration, HA wash, HA elution) 
BK   buffer K (HA wash, HA elution) 
BL   solution L (Cu-IMAC immobilization) 
BM   buffer M (Cu-IMAC equilibration and wash) 
BN   buffer (Cu-IMAC elution) 
BO   solution O (Cu-IMAC stripping) 
BP   buffer P (DsRed dialysis buffer) 
BSA   bovine serum albumin 
c   concentration       [mg/l] 
c0   initial concentration      [mg/l] 
C4P   cellulose-kieselguhr-filter, nominal cutoff 8 µm 
CCF   cell culture fluid 
CEC   cation exchange chromatography 
CFF   cross-flow filtration 
cGMP   current good manufacturing practice 
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CH   constant region of heavy chain of an antibody 
CIP   cleaning in place 
CL   constant region of light chain of an antibody 
cperm   permeate concentration     [mg/l] 
CPV   Canine Parvovirus 
cret   retentate concentration     [mg/l] 
cv.   cultivar 
CV   column volume      [ml] 
Cx   concentration factor 
d   diameter       [cm] 
Da   Dalton 
DF   diafiltration 
DNA   deoxyribonucleic acid 
dsDNA  double stranded DNA 
DsRed   Discosoma red fluorescent protein 
EBA   expanded bed adsorption 
EDTA   ethylenediamintetraacetate 
ELISA   enzyme linked immunosorbent assay 
EMEA   European Medicine Agency 
ER   endoplasmic reticulum 
F7HP   cellulose-kieselguhr-filter, nominal cutoff 1 µm 
Fab   fragment antigen binding 
Fc   fragment crystallizable  
FDA   food and drug administration 
FPLC   fast protein liquid chromatography 
g   acceleration of gravity     [9.81 m/s²] 
GAHAPκ  Ab goat anti human AP-labeled, LC κ-specific 
GAHFc   Ab goat anti human, Fc-specific 
GC/MS  gas chromatography / mass spectroscopy 
gp120   HIV hull glycoprotein, size 120 kDa 
h   hour 
HA   hydroxyapatite 
HAc   acetic acid 
HC   heavy chain of an antibody 
HCl   hydrochloric acid 
HCP   host cell protein 
HETP   height equivalent of a theoretical plate 
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HFF   hollow-fiber filtration 
HIV   human immunodeficiency virus 
HPLC   high performance (pressure) liquid chromatography 
HW   hardware 
I/O   input / output 
IgG   immunoglobulin HC isotype γ 
IgG1(κ)  immunoglobulin HC isotype γ1, LC isotype κ 
IMAC   immobilized metal ion affinity chromatography 
IQ   installation qualification 
ISO   International Organization for Standardization 
kg   kilogram 
l   liter 
L   column length       [cm] 
LC   light chain of an antibody 
LC/MS   liquid chromatography / mass spectroscopy 
m   meter 
M   molarity       [mol/l] 
MA   membrane adsorber 
mAb   monoclonal antibody 
MC   membrane chromatography 
MCB   master cell bank 
min   minute 
MMC   multimodal cation exchanger 
MS   mass spectroscopy 
MSB   master seed bank 
MV   membrane volume      [ml] 
N   number of theoretical plates 
NBT   Nitro blue tetrazolium chloride 
NMWCO  nominal molecular weight cutoff 
NTU   nephelometric turbidity unit 
OQ   operational qualification 
PAGE   polyacrylamide gel electrophoresis 
PB2   depth filter post bioreactor type 2 
PBS   phosphate buffered saline 
PBS-T   PBS with Tween20 
PC   personal computer 
PC1   depth filter post centrifuge type 1 
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pin   inlet pressure       [bar] 
PLC   Programmable Logic Controller (equal to German „SPS“) 
PMP   plant made pharmaceutical 
PNPP   p-Nitrophenyl Phosphate 
pperm   permeate pressure      [bar] 
ppm   parts per million 
ppb   parts per billion 
pret   retentate pressure      [bar] 
QM   quality management 
RO   reversed osmosis 
rAb   recombinant antibody 
rpm   rotation per minute       [min-1] 
RT   room temperature 
RT2   Reactron2 (laboratory scale) 
RT50   Reactron50 (pilot scale) 
RU   response unit 
Rubisco  Ribulose-1,5-bisphosphat Carboxylase/Oxygenase 
s   second 
S5P   cellulose-kieselguhr-filter, nominal cutoff 0.3 µm 
scFv   single chain fragment variable 
SDS   sodium dodecylsulfate 
SEC   size exclusion chromatography 
SFT   sample flow-through 
SOP   standard operating procedure 
SPR   surface plasmon resonance 
tc   contact time       [min] 
TC   Tri-clamp (sanitary connection) 
TFF   tangential flow filtration 
TMP   transmembrane pressure     [bar] 
TSP   total soluble protein      [mg/ml] 
Tris   Tris(hydroxymethyl)-aminomethan 
UF   ultrafiltration 
URS   user requirement specification 
UV280   ultra violet light of 280 nm wave length 
V   volt 
V0   column volume      [ml] 
Ve   elution volume 
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VH   variable region of heavy chain of an antibody 
VL   variable region of light chain of an antibody 
vlin   linear flow rate      [cm/h] 
vvol   volumetric flow rate      [ml/min] 
v/v   volume per volume 
w/v   weight per volume 
WCB   working cell bank 
WSB   working seed bank 
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VII.4 Automated chromatography methods 
VII.4.1 Capturing in pilot scale with BioProcess 
¤  (Main) 
  0.00  Base  Volume  
  0.00  PIA111  2.00 (bar) 0.0 (bar) 1.75 (bar) 0.00 (bar) 0.00 (bar) Enabled  
  0.00  Inlet  Inlet1 Closed  
  0.00  BubbleTrap/Filter  Inline  
  0.00  Column  DownFlow  
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  0.00  Outlet  Waste  
  0.00  Flow  20 (l/hour)  
¤  0.00  Block  Baseline 
    (Baseline) 
    0.00  Base  SameAsMain  
    1.80  AIR131AZ   
    2.00  End_Block   
¤  0.00  Block  Loading 
    (Loading) 
    0.00  Base  SameAsMain  
    0.00  Injection_Mark   
    0.00  Inlet  Sample Closed  
¤    0.00  Watch_AIS131UV  Greater_Than 0.1 (AU) Outlet1  
      (Outlet1) 
      0.00  Base  SameAsMain  
      0.00  Outlet  Outlet1  
      0.00  End_Block   
    2.00  Watch_AS151  Equal 1 END_BLOCK  
    5.00  Message  "Sampling now!" Screen "notify"  
    5.00  Set_Mark  "SFT#1"  
    10.00  Message  "Sampling now!" Screen "notify"  
    10.00  Set_Mark  "SFT#2"  
    15.00  Message  "Sampling now!" Screen "notify"  
    15.00  Set_Mark  "SFT#3"  
    20.00  Message  "Sampling now!" Screen "notify"  
    20.00  Set_Mark  "SFT#4"  
    25.00  Message  "Sampling now!" Screen "notify"  
    25.00  Set_Mark  "SFT#5"  
    30.00  Message  "Sampling now!" Screen "notify"  
    30.00  Set_Mark  "SFT#6"  
    35.00  Message  "Sampling now!" Screen "notify"  
    35.00  Set_Mark  "SFT#7"  
    40.00  Message  "Sampling now!" Screen "notify"  
    40.00  Set_Mark  "SFT#8"  
    45.00  Message  "Sampling now!" Screen "notify"  
    45.00  Set_Mark  "SFT#9"  
    50.00  Message  "Sampling now!" Screen "notify"  
    50.00  Set_Mark  "SFT#10"  
    55.00  Message  "Sampling now!" Screen "notify"  
    55.00  Set_Mark  "SFT#11"  
    60.00  Message  "Sampling now!" Screen "notify"  
    60.00  Set_Mark  "SFT#12"  
    60.00  Watch_Off  AS151  
    60.00  End_Block   
¤  0.00  Block  Washing 
    (Washing) 
    0.00  Base  SameAsMain  
    0.00  Inlet  Inlet1 Closed  
    0.00  Message  "Loading finished" Screen "notify"  
¤    0.00  Watch_AIS131UV  Less_Than 0.5 (AU) Outlet2  
      (Outlet2) 
      0.00  Base  SameAsMain  
      0.00  Outlet  Outlet2  
¤      0.00  Watch_AIS131UV  Less_Than 0.015 (AU) stableUV  
        (stableUV) 
        0.00  Base  SameAsMain  
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        0.00  Watch_AIS131UV  Stable_Baseline (3)#UV_Baseline (Minutes) END_BLOCK  
        0.00  End_Block   
      0.00  End_Block   
    (25.00)#Wash1_Vol  End_Block   
¤  0.00  Block  Washing2 
    (Washing2) 
    0.00  Base  SameAsMain  
    0.00  Watch_Off  AIS131UV  
    0.00  Inlet  Inlet2 Closed  
    0.00  Set_Mark  "10 mM NaPi"  
¤    0.00  Watch_CIS102  Less_Than 2 (mS/cm) stableCond  
      (stableCond) 
      0.00  Base  SameAsMain  
      0.00  Watch_CIS102  Stable_Baseline 3 (Minutes) END_BLOCK  
      0.00  End_Block   
    7.00  Watch_Off  CIS102  
    7.00  End_Block   
¤  0.00  Block  FilterChange 
    (FilterChange) 
    0.00  Base  Time  
    0.00  ManFlow  50 (%)  
    0.00  Message  "Ventil auf Waste, Inlinefilter wechseln + entlüften!" Screen "notify"  
    0.00  Pause  INFINITE (Minutes)  
    0.00  Inlet  Inlet3 Closed  
    2.50  Message  "Ventil auf MA zurückstellen!" Screen "notify"  
    2.50  Message  "Outlet 3 in Flasche hängen!" Screen "notify"  
    2.50  Pause  INFINITE (Minutes)  
    2.50  End_Block   
¤  0.00  Block  Elution 
    (Elution) 
    0.00  Base  SameAsMain  
    0.00  Flow  6 (l/hour)  
¤    0.25  Watch_AIS131UV  Slope_Greater_Than 0.10 (per min) Outlet3  
      (Outlet3) 
      0.00  Base  SameAsMain  
      0.00  Outlet  Outlet3  
      0.00  Message  "Outlet 2 in Flasche hängen!" Screen "notify"  
¤      0.20  Watch_AIS131UV  Less_Than 0.075 (AU) Outlet2b  
        (Outlet2b) 
        0.00  Base  SameAsMain  
        0.00  Outlet  Outlet2  
        0.60  End_Method   
    5.00  End_Block   
VII.4.2 Production scale method for BioProcess controller 
Main method: 
¤  (Main) 
  0.00  Base  Volume  
  0.00  PIA111  2.00 (bar) 0.00 (bar) 1.90 (bar) 0.00 (bar) 0.00 (bar) Enabled  
  0.00  Inlet  Inlet1 Closed  
  0.00  BubbleTrap/Filter  Inline  
  0.00  Column  Bypass  
  0.00  Outlet  Waste  
  0.00  Flow  24 (l/hour)  
¤  0.00  Block  Baseline 
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    (Baseline) 
    0.00  Base  SameAsMain  
    0.80  AIR131AZ   
    1.00  End_Block   
  0.00  Column  DownFlow  
¤  0.00  Block  WashingA 
    (WashingA) 
    0.00  Base  SameAsMain  
    0.00  Flow  10 (l/hour)  
    0.00  Inlet  Inlet1 Closed  
    0.00  Outlet  Outlet1  
    0.20  Flow  24 (l/hour)  
¤    0.50  Watch_AIS131UV  Less_Than 0.015 (AU) stableUV  
      (stableUV) 
      0.00  Base  SameAsMain  
      0.00  Watch_AIS131UV  Stable_Baseline (3)#UV_Baseline (Minutes) END_BLOCK  
      0.00  End_Block   
    (10.00)#Wash1_Vol  End_Block   
¤  0.00  Block  WashingB 
    (WashingB) 
    0.00  Base  SameAsMain  
    0.00  Watch_Off  AIS131UV  
    0.00  Inlet  Inlet2 Closed  
    0.00  Set_Mark  "10 mM NaPi"  
¤    0.00  Watch_CIS102  Less_Than 2 (mS/cm) stableCond  
      (stableCond) 
      0.00  Base  SameAsMain  
      0.00  Watch_CIS102  Stable_Baseline 3 (Minutes) END_BLOCK  
      0.00  End_Block   
    10.00  Watch_Off  CIS102  
    10.00  End_Block   
¤  0.00  Block  Pre_Elu_Flush 
    (Pre_Elu_Flush) 
    0.00  Base  SameAsMain  
    0.00  Message  "Stop quattroflow pump" Screen "notify"  
    0.00  Inlet  Inlet3 Closed  
    0.00  Column  Bypass  
    0.00  Outlet  Waste  
    0.00  Message  "Outlet2 in Flasche und Outlet3 in Becher hängen" Screen "doorbell"  
    0.05  ManFlow  50 (%)  
    2.70  ManFlow  5 (%)  
    2.90  Flow  6 (l/hour)  
    3.00  End_Block   
¤  0.00  Block  Elution 
    (Elution) 
    0.00  Base  SameAsMain  
    0.00  Flow  6 (l/hour)  
    0.00  Inlet  Inlet3 Closed  
    0.00  Column  DownFlow  
    0.00  Outlet  Outlet1  
    0.00  Injection_Mark   
¤    0.30  Watch_AIS131UV  Slope_Greater_Than 0.10 (per min) Outlet2  
      (Outlet2) 
      0.00  Base  SameAsMain  
      0.00  Outlet  Outlet2  
¤      0.20  Watch_AIS131UV  Less_Than (0.060)#lower_collecting_limit (AU) Outlet3  
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        (Outlet3) 
        0.00  Base  SameAsMain  
        0.00  Outlet  Outlet3  
        0.00  Flow  18 (l/hour)  
        0.50  Flow  25 (l/hour)  
        0.50  Outlet  Waste  
        0.50  Message  "Continue loading with quattroflow!" Screen "drumroll"  
        0.50  End_Block   
    1.00  End_Block   
  0.00  New_Chromatogram  CIP  
  0.00  Injection_Mark   
  0.00  Flow  25 (l/hour)  
¤  0.00  Block  CIP_10mM_NaPi 
    (CIP_10mM_NaPi) 
    0.00  Base  Volume  
    0.00  Inlet  Inlet2 Closed  
    0.00  Column  DownFlow  
    0.00  Outlet  Waste  
    2.00  End_Block   
¤  0.00  Block  CIP_NaOH_NaCl 
    (CIP_NaOH_NaCl) 
    0.00  Base  SameAsMain  
    0.00  Inlet  Sample Closed  
    0.00  Column  DownFlow  
    0.00  Outlet  Waste  
    (5.00)#Vol_CIP  End_Block   
¤  0.00  Block  EQ_bufferA 
    (EQ_bufferA) 
    0.00  Base  SameAsMain  
    0.00  Inlet  Inlet1 Closed  
    0.00  Column  DownFlow  
    0.00  Outlet  Waste  
    (7.00)#EQ_Vol_BA_end  End_Block   
VII.4.3 Automated polishing with HA column in laboratory scale 
¤  (Main) 
  0.00  Base  Volume  
  0.00  AutoZeroUV   
  0.00  Wavelength  280 (nm) 260 (nm) OFF (nm)  
  0.00  Alarm_Pressure  Enabled 2 (MPa) 0.00 (MPa)  
  0.00  Flow  1 (ml/min)  
  19.50  AutoZeroUV   
  20.00  InjectionValve  Inject  
  20.00  Fractionation_900  10 (ml)  
  30.00  InjectionValve  Load  
  40.00  Gradient  19 (%B) 0.00   
  40.00  PumpBInlet  B1  
  60.00  Gradient  43 (%B) 0.00 (base)  
  100.00  Gradient  100 (%B) 0.00 (base)  
  130.00  Gradient  100 (%B) 0.00 (base)  
  130.00  PumpBInlet  B2  
  140.00  Fractionation_Stop_900   
  150.00  Gradient  0.0 (%B) 0.00 (base)  
  150.00  PumpBInlet  B1  
  150.00  PumpAInlet  A2  
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  170.00  PumpWashPurifier  OFF OFF ON OFF  
  170.00  End_Method 
VII.4.4 Automated analytical SEC with Autosampler A900 
¤  (Main) 
  0.00  Base  CV 23.562 (ml) Superdex_200_HR_10/30  
  0.00  Alarm_Pressure  Enabled 1.5 (MPa) 0.00 (MPa)  
  0.00  Wavelength  280 (nm) 260 (nm) OFF (nm)  
  0.00  ColumnPosition  Position7  
  0.00  Pause  0.1 (Minutes)  
  0.00  Flow  0.3 (ml/min)  
  0.18  AutoZeroUV   
  0.20  InjectionFlushed  (1)#Vialnr Yes Air  
  0.20  Pause  0.02 (Minutes)  
  0.20  Message  (Sample_ID)#Sample_ID Screen "No sound"  
  1.30  End_Method   
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